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PROTOCOL AMENDMENT FOR: 
 
P-001-05-01-01 – STUDY PROTOCOL FOR A MULTINATIONAL PHASE II STUDY (PROOF-OF-
CONCEPT) OF THE ASSESSMENT OF AN ABRIDGED MELARSOPROL SCHEDULE AGAINST 
LATE STAGE T. B. RHODESIENSE SLEEPING SICKNESS.  
 
This amendment modifies the original Protocol (dated 03.03.2006). The purpose of the amendment is 
to:  
1. Substitution of ibuprofen by paracetamol.  
Thrombocytopenia is commonly observed in T.b. rhodesiense patients. In order not to take the 
risk of influencing platelet aggregation by administration of a cyclooxygenase inhibitor 
(ibuprofen) it was decided to treat fever and pain with paracetamol (standard therapy).  
2. Minor language editing - the content has not been changed; therefore the changes are not 
listed in the following paragraph.  
 
Section 5.1.4, Discussion of Study Design 
Was: 
In order to reduce pain, fever and inflammatory processes, ibuprofen will be administered twice a day. 
Adults receive twice 400mg; children twice 100mg. Ibuprofen administration will start on the day 
patients have to undergo LP.  
Changed to: 
In order to reduce fever and pain, paracetamol will be administered twice a day. Patients with a 
bodyweight ≥30 kg will receive twice 500mg; patients with bodyweight ≤30kg twice 250mg. 
Paracetamol administration will start on the day patients have to undergo LP.  
 
Section 5.3.1, Treatment schedule 
Was: 
Table 4: Concomitant treatments during IMPAMEL III trials: 
Concomitant treatments 
Steroids   centre specific: Uganda:  Hydrocortison when reaction occurs. 
     Tanzania:  Prednisolone (10mg) half an hour before 
       melarsoprol administration. 
Anticonvulsive drugs  centre specific 
Ibuprofen  Patients (≥ 30kg):  400mg every 12 hours  
   Patients (≤ 30kg):  200mg every 12 hours 
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Changed to: 
Table 4: Concomitant treatments during IMPAMEL III trials: 
Concomitant treatments 
Steroids   centre specific: Uganda:  Hydrocortison when reaction occurs. 
     Tanzania:  Prednisolone (10mg) half an hour before 
       melarsoprol administration. 
Anticonvulsive drugs  centre specific 
Paracetamol  Patients (≥ 30kg):  500mg every 12 hours  
   Patients (≤ 30kg):  250mg every 12 hours 
 
Section 5.3.4, Supplementary medication before melarsoprol treatment (standard if no rules 
exist) 
Was: 
Malaria: centre specific diagnosis and treatment. 
Helminthic infections: centre specific diagnosis and treatment. 
Mebendazole: Day one to three: 100 mg total dose twice daily. 
Ibuprofen: before and after LP. 
Changed to: 
Malaria: centre specific diagnosis and treatment. 
Helminthic infections: centre specific diagnosis and treatment. 
Mebendazole: Day one to three: 100 mg total dose twice daily. 
Paracetamol: before and after LP. 
 
Section 5.3.5, Supplementary medication during melarsoprol treatment 
Was: 
Each patient will receive ibuprofen twice a day (every 12 hours). Patients (≥ 30kg) receive twice 
400mg; patients (≤ 30kg) will receive twice 200mg.  
Changed to: 
Each patient will receive paracetamol twice a day (every 12 hours). Patients (≥ 30kg) receive twice 
500mg; patients (≤ 30kg) will receive twice 250mg.  
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Abstract 
Sleeping sickness caused by Trypanosoma brucei rhodesiense (T.b. rhodesiense) has a very fast and 
acute progression, being fatal in order of weeks to a few months when left untreated. Melarsoprol 
remains the only drug for the treatment of the late stage of the disease. Melarsoprol is very toxic and 
has to be administered parenterally on a repeated basis. Serious adverse drug reactions and long 
treatment schedules result in high case fatality rates, low treatment quality and compliance. Between 
1996 and 2004 the safety, efficacy and effectiveness of a new, abridged melarsoprol treatment has 
been investigated in countries affected by Trypanosoma brucei gambiense (T.b. gambiense). Due to 
its considerable socio-economic benefits, better cost-effectiveness and clinical non-inferiority, the 10-
day melarsoprol treatment schedule was adopted as new, national treatment policy in countries 
fighting T.b. gambiense infections at the International Scientific Committee for Trypanosomiasis 
Research and Control / ISCTRC meeting in 2003. However, clinical testing of the 10-day schedule in 
T.b. rhodesiense is still outstanding despite several recommendations. It is now high time to carry out 
this work in order to offer affected patients a potentially improved schedule on the basis of an existing 
drug.  
 
Design 
This is a two-centre, multi-national, non-controlled clinical trial. 60 subjects (≥6 years of age) are 
enrolled in 2 trial sites (Lwala Hospital, Kaberamaido District, Uganda, Kaliua Health Centre, Urambo 
District, Tanzania) in order to evaluate the primary efficacy endpoint (end of treatment) of the abridged 
melarsoprol treatment against late stage T.b. rhodesiense sleeping sickness.  
Trial 1: Suramin pre-treatment & 10-day melarsoprol schedule 
2x15 late stage T.b. rhodesiense patients receive suramin (dosage according to centre specification) 
followed by a continuous melarsoprol application for 10 days at a dosage of 2.2 mg/kg (but a 
maximum of 180mg).  
Trial 2: 10-day melarsoprol schedule 
2x15 late stage T.b. rhodesiense patients are treated with a continuous melarsoprol application for 10 
days at a dosage of 2.2 mg/kg (but a maximum of 180mg).  
To follow: 
In a controlled, randomized, comparative, multi-centre multi-national, clinical trial the treatment 
schedule of whether trial 1 or 2 will be tested against the country’s respective treatment policy.  
 
Objectives 
1. The primary objective of this study is to assess the safety, tolerability and efficacy of the 
abridged 10-day melarsoprol treatment schedule in late stage T.b. rhodesiense patients. 
2. The secondary objective of this study is to investigate the role of the suramin pre-treatment in 
late stage therapy.  
3. The third objective of this study is to collect additional blood samples of each patient in order 
to (I) monitor the potential geographical overlap of the T.b. gambiense and T.b. rhodesiense 
foci in Uganda, (II) distinguish relapses from re-infections in case of positive follow-up visits 
and (III) to carry out HLA-genotyping in order to correlate the occurrence of ES with the 
respective HLA-genotypes. 
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Abbreviations used: 
 
BBB Blood Brain Barrier 
CNS Central Nervous System 
CRF Case Report Form 
CSF Cerebrospinal fluid 
ES Encephalopathic syndrome 
HLA Human Leukocyte Antigen System 
ISCTRC International Scientific Committee for Trypanosomiasis Research and Control 
IDP’s  Internally Displaced People 
i.v. Intravenous 
LIRI Livestock Health Research Institute, Uganda 
LP Lumbar puncture 
HAT Human African Trypanosomiasis 
MoH Ministry of Health 
NIMR National Institute for Medical Research (Tanzania) 
PCR Polymerase Chain Reaction 
p.o. per os 
SAB Scientific Advisory Board 
SRA-gene Serum-resistance-associated gene 
SS Sleeping Sickness 
STI Swiss Tropical Institute 
WBC White blood cells (leucocytes) 
WHO World Health Organization 
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3. Introduction 
3.1. Overview of Human African Trypanosomiasis 
Human African Trypanosomiasis (HAT), better known as sleeping sickness is caused by the protozoan 
parasites Trypanosoma brucei gambiense (West African form of the disease) and Trypanosoma brucei 
rhodesiense (East African form of the disease). The occurrence of the two species is more or less 
separated by the Great Rift Valley. T.b. gambiense is a very homogeneous parasite species whereas 
T.b. rhodesiense is very heterogeneous. T.b. rhodesiense is a zoonotic disease; host animals are 
game animals as well as domestic livestock. Both parasites are transmitted in the saliva of blood-
sucking female tsetse flies (Glossina spp.), found in a belt that stretches between South of the Sahara 
and North of the Kalahari. During the 1950's, sleeping sickness was practically brought under control. 
Following the attainment of independence from colonial rule, sleeping sickness control has not been 
given sufficient attention by national health authorities. Social, political and economical development of 
rural areas, increased population movements, civil disturbances and reduced willingness of the people 
to submit to medical examination, yet aggravated this situation. The prevalence rate of 
trypanosomiasis rose again from 0.01 % of the population up to 1-2 %1. Currently, the disease affects 
36 out of 53 African countries where all, or part of the population, is at risk of infection. Some 60 
million people live at risk of contracting the disease, but no more than 3 to 4 million are under 
adequate surveillance2. WHO estimates that at least 300’000 individuals are infected, and the annual 
incidence of reported new cases is approximately 20’000 – 40’000 which certainly is an 
underestimation2. However, the importance of HAT with regard to public health lies not in the annual 
incidence, but in its potential for development of explosive epidemics3. If only the incidence is 
considered, HAT appears to be a minor health problem compared to other parasitic diseases like 
malaria and helminthic infections. However, even single cases or endemic outbreaks can severely 
affect whole families, the local economic situation and large scale epidemics were fatal for many 
thousand people in the past. If the DALY figures (e.g. loss of healthy life years by premature mortality 
and disability) are considered, the social and economic impact of trypanosomiasis even ranks third of 
all parasitic diseases behind malaria and schistosomiasis in sub-Saharan Africa4. 
The clinical profile of HAT is too diffuse to allow for a direct differential diagnosis. Only the proof of the 
parasites presence in blood, lymph nodes or cerebrospinal fluid is sufficient. T.b. gambiense can be 
sero-diagnosed with the CATT test (Card Agglutination Test) followed by microscopic confirmation of 
the parasite in blood and/or lymph. The diagnosis of T.b. rhodesiense has to entirely rely on 
microscopy. The sensitivity of this method is dependent on the level of parasitaemia and the 
technicians’ experience. Unfortunately, no other diagnostic methods are available. Once the presence 
of trypanosomes in blood and/or lymph is confirmed, a lumbar puncture has to follow for stage 
determination. The two parasites are morphologically identical and differentiation is only possible by 
analysis of isoenzymes and /or DNA-analysis.  
The clinical presentation of Rhodesian and Gambiense sleeping sickness is remarkably different. The 
highly virulent T.b. rhodesiense causes a precipitated evolution of the disease (down to 8 days 
between infective bite and the presence of trypanosomes in the cerebrospinal fluid5, while the less 
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virulent T.b. gambiense about low parasitaemias, elusive and mild symptoms for months, and 
insidious evolution towards the nervous stage6.  
T.b. rhodesiense infections presents as an acute febrile illness that is fatal within weeks or months if 
left untreated7. At the site of the infective bite with T.b. rhodesiense, parasites proliferate and, 
occasionally, lead to nodule or ulcer called a chancre, involving widespread lymph node enlargement. 
It is very difficult to distinguish such symptoms in the beginning from other tropical fevers, such as 
malaria, bacterial meningitis or enteric fever. The parasite becomes established in the blood and it 
multiplies, with intermittent fever, splenomegaly and often signs of myocardial involvement. The study 
of the duration of symptoms and the case fatality of T.b. rhodesiense showed that the disease 
progressed to the stage of central nervous system involvement between three weeks to two months of 
infection. Compared to the Gambiense form, less demarcation between first and second stage illness 
is observed. The CNS involvement in T.b. rhodesiense infections can be clinically limited to 
drowsiness and tremor8. Most (> 80%) deaths occurred within six months of illness9, often due to 
cardiac failure or secondary infections.  
Clinical symptoms of Gambiense trypanosomiasis commence by an uncharacteristic general malaise. 
Typical but not characteristic signs and symptoms are fever, headache, joint pains, transient oedema, 
pruritus and lymphadenopathy may accompany the so-called first or haemolymphatic stage of HAT. 
Typical for T.b. gambiense HAT is the so called Winterbottom sign; enlarged, painless, rubbery 
cervical lymph nodes in the posterior cervical triangle. With the parasite’s penetration to the central 
nervous system patients enter the second or meningoencephalitic stage which ends fatal when left 
untreated. The interval between the start of the infection and the start of the second stage is in the 
order of months or years8 and allows T.b. gambiense patients to live up to 5 to 10 years post-infection. 
In the second stage of the disease neuropsychiatric signs and symptoms occur. Severe 
endocrinological and mental disturbances, such as impotence, infertility, amenorrhea, delirium, mania, 
paranoia, schizoid attacks, aggressive behaviour and severe motor problems are the main signs. 
Until today, the underlying mechanisms of CNS invasion are not known in detail. Frequently observed 
is meningoencephalitis. The meninges are infiltrated with lymphocytes, plasma cells and occasional 
morular (Mott) cells. The inflammatory cell infiltrate extends along the Virchow-Robin spaces into the 
substance of the brain producing the characteristic picture of perivascular cuffing10. An immune 
response is certainly involved in the process; increased levels of antibodies can be detected and thus 
supports the inflammatory process. Further, the number of white blood cells (WBC) as well as the 
protein content is elevated in the cerebrospinal fluid (CSF). This observation is currently used for 
discrimination of first and late stage patients: arbitrarily, if more than 5 WBC per mm3 and/or protein 
content above 25 mg per 100 ml (method of Siccard & Cantaloube) and/or trypanosomes are found in 
the CSF, the patient is considered to be late stage and treated with melarsoprol3. Recent 
investigations have indicated that the WBC count is more reliable than the protein determination2. 
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3.2. Treatment of HAT 
3.2.1. General Aspects 
Only a very limited number of drugs are available for treatment of HAT and there is no vaccination. For 
first stage treatment two drugs are in use: suramin (Germanin™), a polysulphonated naphtylurea, 
applied in T.b. rhodesiense infection and pentamidine (Pentacarinat®), an aromatic diamidine, applied 
in T.b. gambiense infection.  
Suramin was introduced into clinical use in 1920. It is normal clinical practice to start with a test dose 
to assess the patient’s tolerance to the drug. Therefore a dose of 5mg/kg is given on the first day. For 
treatment of the early stage patients receive 5 doses of suramin at a dosage of 20mg/kg of body 
weight (up to a maximum of 1g). Because suramin has a terminal half-life of 92 days11 each of the 5 
doses is spaced by a 5 to 7 day interval. The major adverse drug reaction is nephrotoxicity with renal 
impairment. But also fever, joint pain, pruritus, exfoliative dermatitis, haemolytic anaemia, 
agranulocytosis, jaundice, hepatitis and diarrhea add to the adverse reactions profile. Suramin is a 
highly charged compound and does not cross the BBB. It is administered intravenously as a solution 
of suramin sodium. Due to instability to light the solution has to be freshly prepared before each 
administration. After intravenous administration it circulates in the blood in tight association with serum 
albumin and low density lipoproteins and is taken up slowly by host and parasite, probably by receptor 
mediated endocytosis. The different drug-uptake dynamics of host and parasite are believed to form 
the basis of the dissimilar toxicity profiles. Suramin is deposited in the renal tubes and should not be 
administered to patients with renal disease. Urine should be checked before and during treatment for 
proteinuria.  
For treatment of the late stage of the disease there are no other registered drugs than melarsoprol and 
eflornithine. Melarsoprol, an organo-arsenical drug, was introduced by Friedheim in 1949. Eflornithine 
(α-Difluoromethyl ornithine, DFMO) was first developed as a cytostatic drug and was registered for the 
use against HAT in 1990 (USA) and 1991 (Europe)12. Eflornithine, which is active in T.b. gambiense 
infection has only very limited activity in T.b. rhodesiense due to biochemical reasons13. Melarsoprol, 
respectively its active metabolite melarsen oxide, is effective against both, T.b. rhodesiense and T.b. 
gambiense infections. For treatment of cases refractory to melarsoprol, nifurtimox is used on a 
compassionate base in combination with eflornithine. Nifurtimox, a 5-nitrofuran, is not registered 
against HAT, but was developed for the treatment of Trypanosoma cruzi, the causative agent of 
Chagas' disease.  
Despite the search for new drugs and the introduction of eflornithine, melarsoprol is likely to remain 
the first-line drug for the next decade. For this reason WHO advocates optimization of it’s use2. 
 
3.2.2. Melarsoprol Treatment 
Treatment regimens of melarsoprol used to be empirically determined and vary considerably between 
countries and treatment centres. The treatment regimens for melarsoprol embody a real omnium-
gatherum throughout Africa.  
Melarsoprol treatment in T.b. rhodesiense patients is in general preceded by one or two injections of 
suramin. The pre-treatment is intended to clear parasitaemia in blood and lymph before the treatment 
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with melarsoprol starts. This is thought to prevent from an initial high antigen release which might 
trigger major adverse reactions in second stage treatment and the introduction of trypanosomes in the 
CNS while performing the diagnostic LP. However, there is no solid scientific evidence for this 
approach.  
The current treatment schedules for melarsoprol in East Africa (see Table 1) are three or four series of 
daily i.v. injections (with increasing or equal doses up to a maximum dose of 3.6mg/kg) for 3 or 4 days, 
with intervening rest periods of 5-7 days. At the end of treatment the blood is checked for the absence 
of trypanosomes. Some health facilities also check the CSF at the end of treatment for the absence of 
trypanosomes and the WBC count. Cure can only be confirmed when the patients present for follow-
up examinations, theoretically, after 3, 6, 12, 18 and 24 months. However, the drop-out rates in the 
follow-up period are very high and usually the patients come back for the first follow-up visit only. 
Melarsoprol is a highly toxic drug and adverse drug reactions are frequent limiting the use of the drug 
to the late stage. The major adverse drug reaction in melarsoprol therapy is the potentially fatal 
encephalopathic syndrome (ES). The incidence for ES in Rhodesian sleeping sickness was found to 
be 8% and 5% in the Gambiense form14, the mortality rate amongst those patients affected was 
approximately 50%. Until today, the mechanism of the ES is not fully understood. The current 
hypothesis proposes an immunological reaction15. In order to investigate this hypothesis more in 
detail, an association study was recently carried out: the occurrence of ES was correlated with the 
HLA-genotype of each patient. The HLA-system is highly polymorph and one of the major 
determinants of the immunological response. The alleles of the HLA-system are not only characteristic 
for each individual subject but also for different geographic regions. In a case-control design blood 
samples form T.b. gambiense patients were collected (Democratic Republic of Congo and Angola) 
and HLA-genotyping was performed. The association of the HLA-genotype and the incidence rates of 
ES showed that there is a possible correlation but the samples seize is yet too small14. 
Difficulties of current melarsoprol treatment in East Africa are various: the long hospitalization period 
overextends the health centres capacities; the changing dosages throughout the treatment for each 
individual patient are not accomplished regularly; wrong dosing can influence the frequency of adverse 
drug reactions and the case fatality rates.  
The case fatality rates vary considerably between the different treatment centres. This reflects the 
local situation, e.g. doctors on site, availability of concomitant drugs, quality of the staff, nursing care 
for the patients etc.  
The long hospitalization time presents a major burden for the patients and their families. The 
intermitted resting periods extends the hospital stay to up to one month or longer. This, together with 
the often long distances to the treatment centres lead to significant financial burden for the affected 
families. There are reports of patients leaving the health centres after one or two series of melarsoprol 
applications. Insufficient amount of treatment drugs favour relapses and resistances and hamper 
disease control on a long term basis.  
Another problematic progression in melarsoprol treatment is an increasing number of refectory cases 
observed in Gambiense sleeping sickness. Growing number of patients, 20-25% in certain foci, do not 
respond to melarsoprol treatment, probably due to resistance16. Currently, two approaches are used to 
treat refractory cases: a) repetitive melarsoprol treatment, very often with limited success or b) the use 
combination treatment (eflornithine–nifurtimox & melarsoprol–nifurtimox). Clinical trials for testing 
IMPAMEL III / Amendment to Protocol  Page 14 of 60 
Company Confidential – Swiss Tropical Institute  
Protocol P-001-05-01-02 
combination treatments are ongoing. Likely such a scenario will sooner or later also be required for 
treatment of T.b. rhodesiense in the lack of alternatives. Since eflornithine is not sufficiently effective in 
T.b. rhodesiense combinations with melarsoprol will be used. To achieve this, the abridged treatment 
schedule will be most helpful.  
Recent reports by field workers about suramin resistance (unpublished) are a further concern. The 
parasites are exposed in first as well as in second stage treatment to suramin. Especially in second 
stage treatment very low doses are applied. The frequent uses of the drug at low doses may influence 
the development and dynamics of resistance.  
 
3.2.3. Development of a new, abridged melarsoprol schedule against late stage infections 
Even though melarsoprol was introduced in 1949 only recently its pharmacokinetic and 
pharmacological properties have been investigated17-20. Based on pharmacokinetics and computer 
simulations, a new schedule for late stage sleeping sickness was suggested. The alternative treatment 
schedule consists of a daily melarsoprol application at a dosage of 2.2mg/kg for 10 consecutive days. 
This leads to a reduction of the total amount of given drug of up to 30% and a reduced hospitalization 
time from about 30 to 14 days.  
 
3.2.3.1. Safety, efficacy and effectiveness of the IMPAMEL schedule 
Between 1996 and 2004 the safety, efficacy and effectiveness of the “Improved Melarsoprol 
Application – IMPAMEL” –schedule was clinically tested and developed.  
The IMPAMEL I program assessed the safety and efficacy of this new, abridged treatment regimen by 
conducting an open, randomized equivalence trial in 500 T.b. gambiense patients in Angola. There 
were no significant differences in the frequency of adverse drug reactions and efficacy, and the new 
schedule was found to be favourable over the Angolan standard 26-day treatment schedule. The 
positive impression of the new treatment schedule was corroborated by the results of a multi-national, 
multi-centre study, monitoring the application of the new schedule in over 2’800 patients in various 
different settings (IMPAMEL II program) and the effectiveness was similar to the respective standard 
treatment regimens21.  
The IMPAMEL schedule doesn’t improve the occurrence and/or frequency of adverse events which are 
related to the toxicity of melarsoprol. No significant clinical inferiority of the new schedule could be 
demonstrated. But the IMPAMEL schedule is very much favourable due to socio-economic benefits: with 
a similar efficacy and effectiveness over the standard regimens, the hospitalization time can be 
reduced by approximately 50%, the total amount of given melarsoprol by about 30%. Those factors 
facilitate late stage treatment on different levels: no more dose-adjusting, reduced hospitalisation time 
which relieves the health facilities, the patients and their families. Those factors have a high impact on 
the capacity of each treatment centre, on the treatment quality and compliance. Within the IMPAMEL II 
program a cost-effectiveness study was undertaken and the results confirmed that the new schedule 
reduces treatment and hospitalisation costs per patient.  
On request of WHO, the new 10-day schedule for treatment of late stage T.b. gambiense sleeping 
sickness with melarsoprol was recommended by the International Scientific Council for 
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Trypanosomiasis Control and Research / ISCTRC at the occasion of the 27th meeting in October 2003, 
Pretoria, South Africa.  
 
3.3. HAT Situation in East Africa 
East Africa is affected by HAT in many different foci. Political unrest, civil wars and poverty result in 
large civil- and livestock movements which bear the potential of importing sleeping sickness to new 
areas. The establishment of control measures and interventions is very difficult and is hampered by 
the lack of financial means, reliable diagnostic tools, well trained personnel, access to health centres 
and by the high toxicity of the drugs in use. The HAT foci are spread over the rural areas where the 
population lives predominately from farming. Livestock is closely linked to their daily life; the close 
contact between humans and animals increases the risk of transmission. Game animals were the 
main reservoir in the past but today the domestic livestock (cattle and pigs) represent the most 
important animal reservoir for T.b. rhodesiense. The transmission from animals to humans takes place 
in the fields, cattle markets etc. Because of the high T.b. rhodesiense virulence, epidemics can quickly 
spread and cause substantial losses in human and economic sectors. Sleeping sickness has a 
considerable social and economic impact, with direct monetary losses plus indirect productivity losses (lost 
milk production, loss of market value). In Uganda, for example, the annual losses caused by T.b. 
rhodesiense are estimated at more than US$ 1.3 billion22. 
The existing diagnostic tools and treatment are very unsatisfactory. Most cases are diagnosed in the 
late stage of the disease only. Whether because the patients present at the health facility only after 
several visits to the traditional healers, or because the financial means were not sufficient for 
transport, or even because the detection of parasites was only confirmed after several visits in the 
health facilities. Another frequent reason for not seeking treatment in an early stage of the disease is 
the HIV epidemic: the local population believes that any sign or symptom of a disease is related to an 
HIV infection. There are multi-factorial reasons which can lead to a late diagnosis when melarsoprol 
remains the only possible treatment. The toxicity of melarsoprol causes many adverse drug reactions 
of which some can be fatal. The case fatality rates are in average around 9% but vary substantially 
between different treatment centres. The availability of concomitant treatments, the nutritional status of 
the patients, other infections and nursing care highly influences the case fatality rates.  
The current treatment schedules in East Africa are very heterogeneous (Table 1). No standard 
treatment and care is established and a comparison is therefore not viable. Similarities of the 
treatment are found on the level of the suramin pre-treatment and the serial application of melarsoprol. 
Dissimilarities are found on the level of drug dosages, number of melarsoprol series, length of resting 
periods and concomitant treatments.  
Another great difficulty of HAT epidemiology and control in East Africa is the high rate of under-
detection. To formally quantify the level of under-detection of T.b. rhodesiense sleeping sickness 
during an epidemic (1988-1990) in Tororo (Uganda), a decision tree (under-detection) model was 
developed. It was calculated that for every reported death, 12 deaths remained unreported thus being 
equivalent to 92% of not reported deaths23. Uganda, Tanzania and Malawi report 50 to 1500 cases 
annually24 but no quantification of cases can reflect the true impact of the disease. One can only say 
that the situation is very alarming.  
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3.3.1. Uganda 
Uganda is the only country affected by both forms of the disease, T.b. rhodesiense in the South-East 
and T.b. gambiense in North-West of the country. Recently, the two closest foci in the centre of the 
country increased in size and approached each other significantly. A potential overlap of the two 
diseases has become possible and must be monitored carefully25. The two parasites are 
morphologically identical and only well equipped laboratories can distinguish the two parasites by 
animal infection, analysis of isoenzymes and/or DNA characteristics. Considering the capacities of the 
rural areas in Uganda, specific diagnosis of the two parasites is not feasible. T.b. gambiense can be 
sero-diagnosed with the CATT test (Card Agglutination Test), followed by microscopic confirmation. 
T.b. rhodesiense diagnosis can only be performed by microscopic techniques and is highly dependent 
on the level of parasitaemia and the technicians’ experience. Treatments of the two forms of sleeping 
sickness differ in the first stage (pentamidine vs. suramin), as well as in the second stage (eflornithine 
vs. melarsoprol) of the disease. In case of a Gambiense-Rhodesiense overlap, combined with the lack 
of specific diagnosis, melarsoprol would immediately gain treatment priority because eflornithine is 
ineffective against T.b. rhodesiense. The indispensable need of treating each case with the same drug 
and according to the same schedule would quickly be recognized.  
Uganda currently experiences a sleeping sickness outbreak which is ongoing since 1998. Large scale 
livestock movements for poverty reduction were undertaken. In the four years preceding the outbreak, the 
cattle population in the Soroti District grew by 660%26. The movement of T.b. rhodesiense infected cattle 
has resulted in new sleeping sickness foci in this District. The disease spread to the neighbouring 
Kaberamaido District, where more that 133,000 people have been put at risk of contracting the disease. 
The Ministry of Health supported the set up of a new treatment centre in Lwala, Kaberamaido District. 
Trainings and materials were provided by the Ministry of Health. From June 2004 until June 2005 
approximately 205 patients were diagnosed and treated. Considering the last outbreak in Uganda that 
produced more than 4000 new cases in 198627 and the high rate of under-detection, the situation is 
startling and it is high time to implement relevant strategies in order to prevent (I) a further spread of 
the disease and (II) a possible overlap of the two disease zones.  
 
3.3.2. Tanzania 
Rhodesiense sleeping sickness, which was first reported in the 1920s and 1930s, was endemic in 
eight regions of Tanzania: Arusha, Kigoma, Lindi, Mbeya, Kagera, Rukwa, Ruvuma and Tabora. The 
disease tends to be concentrated in the North-West of the country, in Kigoma. In the past seven years 
only five regions have reported sleeping sickness cases; a large number originated in Kigoma 
(Kibondo and Kassulu districts).  
Currently, between 4 and 5 million people are thought to be at risk of infection in Tanzania, but only 
1% of these are under regular surveillance. In the past 30 years, the number of new cases reported 
annually has risen above 500 (Annual Sleeping Sickness Reports for Tanzania 1965-1995)28.  
The Tabora Station of the National Institute of Medical research (NIMR) supports all HAT activities in 
the area. Health centres in the region are sparse and most of them are not accessible throughout the 
year. For sleeping sickness, the Kaliua Health centre (Urambo District) has a good reputation and 
patients come from far to receive treatment. Kaliua has reported a very significant increase in number 
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of cases in 2004. Another problematic aspect in Tanzania were T.b. rhodesiense infections of several 
tourists, most of them contracted the disease in Game Parks29. The increased annual incidence of 
tourists in Tanzania further activated discussions about disease control and active surveillance.  
A potential overlap of T.b. gambiense and T.b. rhodesiense sleeping sickness in North-West Tanzania 
is also possible, even if not as acute as in Uganda. As a consequence of the Great Lakes Crisis that 
has developed in Burundi and DRC, the International Federation of Red Cross and Red Crescent 
Societies (IFRC) have established refugee camps in the regions of Kasulu and Kigoma (1997). The 
Kigoma District received a massive influx of Congolese refugees. Especially refugees from DRC can 
potentially be infected with T.b. gambiense. Civil movement is ongoing and a potential overlap of the 
two diseases should be carefully observed. 
 
3.3.3. Malawi 
Out of the 25 districts there are 8 HAT-affected districts in Malawi: Rumphi in the northern region; 
Kasungu, Ntchisi, and Nhotakota in the central region; and Mangochi, Machinga, Chikwawa and 
Mulanje in the southern region24. Sleeping sickness in Malawi presents itself differently in comparison 
to the highly virulent and fulminate disease progression in other East African countries. Even though 
the parasite is clearly defined as T.b. rhodesiense, patients suffer from a chronic form of the disease 
as it is known from T.b. gambiense affected areas.  
Diagnosis and treatment of sleeping sickness in Malawi is only provided at the District Hospitals. No 
regional health facility has the means and/or manpower to diagnose and treat sleeping sickness. Long 
geographical distances and difficulties in transport to the District Hospitals lead to very low numbers of 
passive case detection. Due to widespread poverty and lack of national priority there is no ongoing 
disease control.  
In 2005, Malawi has joined the East African Network for Trypanosomiasis (EANETT). The primary aim 
of this collaboration is to commonly develop and support a National Control Program.  
 
3.3.4. Situation in other East African countries 
Kenya, Mozambique, Rwanda, Zambia and Zimbabwe report sporadic less than 50 cases annually. 
Botswana, Burundi, Ethiopia, Namibia and Swaziland have not reported any cases since 199024.  
But large civil- and livestock movements can easily import T.b. rhodesiense to new areas, or historical 
foci can re-emerge.  
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3.3.5. Current Treatment Protocols in use in Eastern Africa 
 
UGANDA TANZANIA MALAWI KENYA 
Second stage treatment Day of action Dosage Day of action Dosage Day of action Dosage Day of action Dosage 
Suramin  
        
Application 01 1 5mg/kg 1 5mg/kg 1 5mg/kg   
Application 02   3 20mg/kg 2 20mg/kg   
Total Suramin  5mg/kg  25mg/kg  25mg/kg  
 
LUMBAR PUNCTURE (LP) 2  5  3  before treatment  
Melarsoprol 
        
Application 01 3 0.5mg/kg 5 2.2mg/kg 4 3.6mg/kg 1 3.6mg/kg 
Application 02 4 0.72mg/kg 6 2.52mg/kg 5 3.6mg/kg 2 3.6mg/kg 
Application 03 5 1.08mg/kg 7 2.88mg/kg 6 3.6mg/kg 3 3.6mg/kg 
RESTING PERIOD 5 days  7 days  7 days  7 days  
Application 04 11 1.44mg/kg 15 2.88mg/kg 14 3.6mg/kg 11 3.6mg/kg 
Application 05 12 1.80mg/kg 16 3.24mg/kg 15 3.6mg/kg 12 3.6mg/kg 
Application 06 13 2.2mg/kg 17 3.6mg/kg 16 3.6mg/kg 13 3.6mg/kg 
RESTING PERIOD  5 days  7 days  7 days  7 days  
Application 07 19 2.52mg/kg 25 3.6mg/kg 24 3.6mg/kg 21 3.6mg/kg 
Application 08 20 2.88mg/kg 26 3.6mg/kg 25 3.6mg/kg 22 3.6mg/kg 
Application 09 21 3.24mg/kg 27 3.6mg/kg 26 3.6mg/kg 23 3.6mg/kg 
RESTING PERIOD 5 days  7 days    7 days  
Application 10 27 3.6mg/kg     31 3.6mg/kg 
Application 11 28 3.6mg/kg     32 3.6mg/kg 
Application 12 29 3.6mg/kg     33 3.6mg/kg 
Total Melarsoprol  27mg/kg  28.08mg/kg  32.4mg/kg  43.2mg/kg 
Total treatment days 13  11  13  12  
Total hospitalisation days 29  27  26  33  
Additional information 
                
Steroids When reaction occurs Prednisolone during treatment Prednisolone or hydrocortisone during treatment 
Hydrocortisone and saline 
during melarsoprol treatment 
LP on discharge yes  No  yes  yes  
Follow up (in months) passive 3,6,12,24 passive 3,6,12,18,24 passive 3,6,12,24 Active after 3months, passive 6,12,24 
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3.4. Conclusion and Justification 
The new, abridged protocol for melarsoprol30 shows significant socio-economic benefits and better 
cost-effectiveness. Members of the Data and Safety Monitoring Board from the IMPAMEL I & II 
programs expressed their concerns regarding an interruption of the IMPAMEL program fearing it could 
lead to an uncontrolled use of the 10-day schedule in East Africa without reliable data about safety, 
tolerability and efficacy. Also, the WHO Scientific Working Group 2001 recommended the urgent 
conduct of the necessary clinical Phase II trials against T.b. rhodesiense, a call which was repeated by 
a WHO Afro meeting in Kampala, October 2003.  
Like in T.b. gambiense treatments, there is a wide variety of East African treatment schedules in use: 
Kenya, Uganda, Tanzania and Malawi all follow different treatment protocols (Table 1). Similarities are 
the pre-treatment with suramin and the serial application of melarsoprol. Dissimilarities are found at 
the level of suramin and melarsoprol dosage, duration of resting periods and concomitant treatments. 
When implementing the short course in East Africa, several aspects have to be taken into 
consideration: Is the 10-day schedule safe and tolerable for T.b. rhodesiense patients? Is the pre-
treatment with suramin redundant? Does the short course of melarsoprol have any impact on the 
incidence rate of the ES or the case fatality rates?  
In the planning of any clinical program in T.b. rhodesiense sleeping sickness, the difficulties in 
patient’s access and diagnosis and the overall limited total number of patients have to be kept in mind. 
All investigations have therefore to be limited to proof-of-concept studies. This clinical trial protocol 
covers two sequential proof-of-concept trials studies with total enrolment number of 60 patients.  
One objective of the IMPAMEL III project is to investigate the importance of the suramin pre-treatment. 
Currently, the pre-treatment with suramin is administered for two reasons:  
− To avoid the introduction of parasites into the CSF during the diagnostic LP. 
− To clear parasites from blood and lymph in order to reduce the antigen release prior to melarsoprol 
administration. 
The introduction of trypanosomes during LP is theoretically possible. However, the usage of proper 
materials and technical skills make a LP without blood vessel damage possible. In the rare case of 
trypanosome introduction to the CSF, the parasites are hampered in growth and survival as the CSF is 
a suboptimal medium31. Some authors believe that a high initial antigen release can trigger 
immunological overreactions32, e.g. increase the risk of ES and consequently increase mortality. 
However, the dynamics of parasite elimination in the first hours after drug contact are very similar for 
melarsoprol and suramin33; the effect of the low-dosed suramin pre-treatment on the parasites is 
doubtful and will be assessed in these trials. Suramin pre-treatment policies are heterogeneous: in 
Uganda, only one test dose of 5mg/kg is administered; in Tanzania the test dose (5mg/kg) is followed 
by one full dose (20mg/kg). In Malawi the suramin pre-treatment is centre specific: some hospitals 
follow the same schedule as in Tanzania; others do not administer a suramin pre-treatment at all. Also 
Kenya’s doesn’t apply the pre-treatment with suramin anymore.  
The parasite’s exposure to the same drug in first as well as in second stage therapy is suboptimal. 
The insufficient doses used in the pre-treatment of late stage disease are rather prone to trigger drug 
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resistances. Field reports of suramin treatment failures/resistances exist, but unfortunately no scientific 
data is currently available.  
The additional use of suramin may also increase the risk of the patient for adverse drug reactions like 
renal impairment. During the IMPAMEL III trials, proteinuria will be monitored by urine analysis.  
Suramin (Germanin™) is delivered in vials of 1g suramin sodium powder, which upon usage has to be 
dissolved in water and should be used within 15 minutes. Quantities remaining in the vial are not 
suitable for further use. The suramin pre-treatment tends to be uneconomic and the risk-benefit ratio 
should be re-considered.  
The main objective of the IMPAMEL III trials is to assess the safety, tolerability and efficacy of the 10-
day melarsoprol schedule against late stage T.b. rhodesiense sleeping sickness. The IMPAMEL 
schedule consists of 10 consecutive melarsoprol injections at a dosage of 2.2mg/kg. Currently, 
starting doses of national treatment schedules in Tanzania and Malawi are 2.2 mg/kg and 3.6 mg/kg, 
respectively. Only Uganda uses a lower starting dose of 0.36 mg/kg, increasing to a maximum dose of 
3.6mg/kg with no better results regarding case fatality rates and/or ES reported. Late stage treatment 
according to the IMPAMEL schedule, reduces the total amount of given melarsoprol by 20% in Uganda, 
by 23% in Tanzania, by 33% in Malawi and by 50% in Kenya. Generally, there is evidence from former 
studies performed in T.b. gambiense34 that the 10-day abridged treatment schedule leads to a 
comparable frequency of adverse drug reactions as the standard treatment schedule. The only 
exception may be skin reactions (like pruritus, maculopapular eruptions) or very rarely bullous 
reactions, which were observed in a higher frequency in previous trials.  
The current national treatment policies are difficult and result in low treatment compliance, low 
treatment quality and very long hospitalization times: some of the patients leave the health facilities 
before the full melarsoprol course has been administered. This feature favours higher relapse rates 
and may have negative impacts on resistance development. The changing dosages throughout the 
treatment are rarely well implemented and can influence the adverse drug reactions profile. The long 
hospitalization times of the patients and their accompanying relatives reduces the overall capacity of 
the health facilities. The IMPAMEL schedule does not claim clinical superiority, but the socio-economic 
benefits and the better cost-effectiveness make it favourable to the patients, the health facilities and 
the national bodies of disease control. If treatment duration becomes shorter, treatment compliance 
and quality improve and may possibly also influence the health seeking behaviour. The IMPAMEL III 
project emphasizes awareness towards the disease, builds a good platform for capacity strengthening 
and supports the north-south collaborations.  
Because the progression of T.b. gambiense and T.b. rhodesiense sleeping sickness is so different, 
each therapeutic intervention has to be tested separately. The patient’s safety can only be ensured 
when possible differences in pharmacodynamics or –kinetics; or different susceptibilities to the same 
drug can be ruled out. Melarsoprol is a highly toxic compound, and until today, it is the only treatment 
for late stage T.b. rhodesiense patients. It is high time to test the 10-day melarsoprol schedule in East 
Africa: not only to be able to offer a substantial better treatment on the basis of an existing drug, but 
also to form the basis of a harmonization process of all East African treatment protocols in use. Most 
importantly, it can not be excluded, that melarsoprol will loose some of its efficacy against T.b. 
rhodesiense, similar to the phenomenon recently observed in some T.b. gambiense areas35. To test 
and potentially introduce the 10-day schedule in East Africa is a preparatory step for upcoming 
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combination treatments as no alternative drug will be available in the next 5 to 8 years. For 
pharmacological and practical reasons, all attempts for combination treatment with melarsoprol (with 
nifurtimox and eflornithine) are based on the abridged 10-day schedule.  
The incidence rate of the encephalopathic syndromes (ES) under melarsoprol treatment is reported to 
be 8% in Rhodesiense and 5% in Gambiense sleeping sickness14. For about 50% of those cases the 
ES is a fatal event. According to current guidelines in drug safety, melarsoprol would never pass 
today’s standards. Still today, little knowledge and data on the ES is available. In Angola and DRC, an 
association study was recently carried out where the ES was correlated with the HLA-genotype14. 
Unfortunately, the study could not provide enough samples in order to present significant results. 
Within the IMPAMEL III trials each patient is asked to provide a blood sample in order to investigate this 
correlation. Until today, no such data for T.b. rhodesiense is available.  
HAT treatment requires a long-term follow-up of each patient in order to monitor drug safety and cure. 
Usually, patients are asked to present for follow-up visits after 3, 6, 12, 18 and 24 months. The drop-
out rates are high, and on the occasion of the 9th September meeting, WHO formed a draft that 
reduces the follow-up period to one year (3, 6 and 12 months post-treatment). In most of the East 
African countries a maximum of one follow-up visit is recorded.  
Some patients, who suffer from T.b. rhodesiense sleeping sickness, receive treatment and are then 
free of parasites. But only a few weeks later they can have trypanosomes again. Without well 
equipped laboratories it is not possible to classify such cases as relapses or re-infections. The 
IMPAMEL III trial includes a sub-study in order to distinguish relapses from re-infections: every patient is 
asked to provide a reference blood sample at baseline evaluation. In case of a positive follow-up 
result, an additional blood sample is collected. By comparison of the parasites genotype (PCR-
Methodology), it is possible to distinguish relapses from re-infections.  
A highly important aspect in HAT today is a potential overlap of T.b. gambiense and T.b. rhodesiense 
foci. The spread of T.b. rhodesiense is closely linked to civil-and livestock movements and often the 
political situations in the countries affected, lead to large numbers of displaced people. Large-scale 
livestock restocking activities are a common concept for poverty reduction. The sum of such actions 
can causes a potential spread of T.b. rhodesiense. Uganda has just experienced the establishment of 
a new T.b. rhodesiense focus, caused by large livestock movements. Uganda is affected by both 
forms of the disease. In order to monitor the potential geographical overlap, the IMPAMEL III project 
includes a separate blood sample analysis for each patient. Human infective T.b. rhodesiense is 
characterised by the presence of the so-called human-serum-resistance-associated-gene (SRA-
gene)36, which can be detected by conventional PCR.  
The control of a zoonotic disease is very complex and costly: only an integrated approach of human 
and animal health can be an effective, long-term control strategy. With limited resources, priorities are 
set in specific and sensitive diagnosis and safe and effective treatment. However, the diagnostic tools 
of HAT are generally poor. The presence of trypanosomes can only be confirmed by microscopy but 
the two parasites are morphologically identical. A differentiated diagnosis, with the direct 
implementation of a differentiated treatment, is impossible. Standard treatment against first stage T.b. 
gambiense sleeping sickness is a 7-day pentamidine treatment, in first stage T.b. rhodesiense, 
suramin is used over a time period between 15 days (Malawi) to 31 days (Tanzania). For late stage 
therapy, melarsoprol is the standard treatment. However, cases refractory to melarsoprol exist 
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already. Eflornithine, which has proven to be safer than melarsoprol37 when it is properly administered, 
is only active against T.b. gambiense. In case of an overlap of the two disease zones, which treatment 
will a late stage patient receive? How to treat mixed infections? To have at least the IMPAMEL schedule 
tested and implemented in both forms of the disease would greatly facilitate such a scenario. 
As a conclusion, only the successful translation of knowledge and results gained on the level of trial 
sites to the national level will provide a significantly positive contribution to the patient’s quality of life.  
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4. Objectives 
4.1. Primary Objective 
The primary objective is to assess the safety, tolerability and efficacy of the 10-day melarsoprol 
schedule against late stage T.b. rhodesiense infections. 
 
4.2. Secondary Objective 
The secondary objective is to investigate the importance of the suramin pre-treatment.  
 
4.3. Third Objective 
In a sub-study blood samples are collected in order to: 
(I) Monitor the possible geographical overlap of T.b. gambiense and T.b. rhodesiense by 
analyzing all blood samples for the presence of the SRA-gene (PCR).  
(II) Distinction of relapses and re-infections in cases of positive follow-up results. 
(III) Investigation of a possible correlation between the HLA-genotype and the occurrence of 
the ES.  
 
5. Investigational Plan 
The trial protocol was developed in accordance with the Declaration of Helsinki and the ICH Guideline 
on Good Clinical Practice.  
 
5.1. Overall Study Design 
These are two multi-centre, multi-country, non-controlled Phase II (proof-of-concept) trials.  
Trial 1:  2x15 subjects with confirmed late stage T.b. rhodesiense sleeping sickness will receive the 
suramin pre-treatment (dosage according to centre specification) followed by 10 consecutive 
melarsoprol injections at a dosage of 2.2mg/kg (but a maximum of 180mg). 
Trial 2:  2x15 subjects with confirmed late stage T.b. rhodesiense sleeping sickness will receive 10 
consecutive melarsoprol injections at a dosage of 2.2mg/kg (but a maximum of 180mg). 
A total of 60 subjects who satisfy the inclusion and exclusion criteria will be enrolled in order to 
evaluate the primary efficacy endpoint (end of treatment). Enrolment is planned to begin in the second 
quarter 2006 and to be completed within approximately 3 months. The last follow-up evaluation is 
expected to be completed approximately 15 months after the initiation of enrolment. Each patient is 
expected to participate for 12 months including the follow-up period.  
Trial 2 will only be implemented if trial 1 shows safe and successful data (see 5.1.4). 
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The two trial sites are in Uganda and Tanzania: 
1. Lwala Hospital, Kaberamaido District, Uganda  
Lwala is close to Lake Kyoga and accessible by road throughout the year in a maximum 2 hours drive 
from Soroti. The hospital has 100 beds and is financed through a Diocese. Only in the beginning of 
2004 it has been established as HAT treatment centre, as a reaction to a new T.b. rhodesiense focus. 
For HAT patients a UNICEF tent is available, but currently not in use. It has electricity and the 
laboratory is well equipped.  
The HIV prevalence is around 7-10 %. Malaria and helminthic infections are the most common 
diseases.  
 
2. Kaliua Health Centre, Urambo District, Tanzania 
Kaliua is accessible by road (in dry season only) in a maximum 3 hours drive from Tabora. The Kaliua 
Health Centre is a missionary hospital and has 50 beds. In the area of Tabora and Kigoma it has a 
good reputation as HAT treatment centre. There is no electricity and the laboratory is poorly equipped.  
The HIV prevalence is around 7%. Malaria is the most common disease.  
 
Patient recruitment 
Active screening is planned in high prevalence villages for a period of 3 to 6 days.  
In case of insufficient patient numbers at Lwala at study initiation, the programme includes a back-up 
centre. In the main focus is the Serere Hospital. It is close to Lwala and provides HAT diagnosis and 
treatment. Patients from Serere will be transported to Lwala for treatment.  
 
All subjects will undergo baseline microscopic blood examination to demonstrate the presence of 
trypanosomes. In case of a positive result, the diagnostic LP for stage determination (trypanosomes in 
CSF and/or WBC > 5 cells/mm3) follows. The diagnostic LP will be performed centre specific in the 
trial 1 group (after suramin application). Patients in the trial 2 group will directly undergo LP after a 
trypanosome positive blood test. Subjects will undergo safety evaluations including physical 
examination, adverse event monitoring, and collection of concomitant medications throughout the 
treatment period and at the end of treatment evaluation. Subjects will also undergo urinary testing 
(dipstick analysis, Combur 9) for rapid screening for diseases of the kidney and the urogenital tract.  
 
All subjects will undergo blood sampling and LP at baseline evaluation; end of treatment and at follow-
up visits.  
All subjects will undergo urinary testing (dipstick analysis, Combur 9) at baseline evaluation, before 
melarsoprol treatment, end of treatment evaluation.  
Children ≥ 6 years can be enrolled in all sites.  
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5.1.1. Efficacy 
Primary efficacy will be evaluated in blood and CSF at the end of treatment (absence of 
trypanosomes). Secondary efficacy will be evaluated in blood and CSF (absence of trypanosomes) at 
each follow-up visit, 3, 6 and 12 months post-treatment.  
Lumbar puncture will be performed at end of treatment and at all follow-up visits. In the case that 
trypanosomes and/or WBC > 5 cells/mm3 are demonstrated, the patients will be re-treated according 
the centre policy.  
In case of a positive blood test after the end of treatment or at follow-up visits, an additional blood 
sample will be taken (300µl, applied on Gentra Cards) to perform genotyping of the parasite (reference 
sample taken at baseline evaluation) and to define the case as a relapse or re-infection (PCR). Re-
infections will not be considered as relapses or treatment failure.  
Additional assessments of clinical efficacy will be performed at 12 month post treatment (last follow-up 
visit). The 12 month post-treatment evaluation is defined as the test of cure evaluation, based on the 
Draft Informal Consultation from WHO (9Sept2004). 
 
5.1.2. Safety 
The incidence of the encephalopathic syndrome (ES) with a fatal outcome and fatalities with other 
causes of death (e.g. disease related, opportunistic infections) have been set as combined endpoint of 
≥10% (see 5.1.4). 
 
5.1.3. Sub-Study 
5.1.3.1. Blood sample collection for PCR-analysis 
Patients are asked to provide 3, in case of a positive follow-up result, 4 blood samples. Blood sample 
analysis will provide knowledge on: 
1. The possible strain-overlap in Uganda. The presence of the so-called SRA gene should be given 
in each sample.  
2. At baseline evaluation, a reference blood sample from each patient will be taken. In case of 
trypanosome positive results during any follow-up visit, the genotyping of the parasites allows to 
make the distinction between relapses and re-infections.  
3. Genotyping of the HLA-system will be put in correlation with the occurrence of ES14. At baseline 
evaluation a blood sample of each patient will be collected. Analysis will follow within 6 to 9 
months after sample collection.  
At any time during the study, the patient, or investigator, may elect to discontinue a patient’s 
participation in the study.  
 
5.1.4. Discussion of Study Design 
The non-controlled, multi-centre, multi-national Phase II trial is designed to (I) assess the safety, 
tolerability and efficacy of the 10-day melarsoprol schedule against late stage T.b. rhodesiense 
sleeping sickness and to (II) investigate the role of the suramin pre-treatment in second stage T.b. 
rhodesiense treatment. The studies are designed in an iterative manner: trial 1 includes a pre-
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treatment with suramin followed by the abridged 10-day melarsoprol schedule. In case of positive 
results, trial 2 follows, where melarsoprol is administered directly. Diagnosis of trypanosomiasis and 
parasitological response to therapy will be assessed by the use of following tests: microscopic 
examination of blood (thin and/or thick smear), haematocrit centrifugation of blood (WOO)38, 
microscopic examination of CSF fluid (single modified centrifugation) and WBC count. 
The multi-centre, multi-national approach allows to take the high strain heterogeneity of T.b. 
rhodesiense into account: data collection in two different endemic regions increases (I) the data’s 
evidence and (II) reflects the general situation in East Africa in a more realistic angle. The high 
participation-interest of the affected countries during preparatory missions further supported the multi-
national approach. The interest of the respective countries is not only based on the acknowledgement 
of the objective’s importance but also because the 10-day melarsoprol schedule forms the basis any 
further development of treatment policies against second stage T.b. rhodesiense trypanosomiasis.  
The inclusion of children ≥ 6 years of age is considered as ethical and safe. Melarsoprol doses are 
calculated depended on body weight: a safe dose relation ship is best established using the individual 
body weight. Generally, the inclusion of children is a hot spot in international discussions on clinical 
trials. Today, the lack of information on pharmacokinetics and -dynamics in children is considered as 
unethical. Children are amongst the most vulnerable individuals and it is important to include children 
in the clinical development of new drugs and new therapeutic approaches. One sensitive topic to 
consider is that children can not give informed consent. Within the IMPAMEL III trials, parents will be 
asked to give consent for their children. 
In order to reduce fever and pain, paracetamol will be administered twice a day. Patients with a 
bodyweight ≥30 kg will receive twice 500mg; patients with bodyweight ≤30kg twice 250mg. 
Paracetamol administration will start on the day patients have to undergo LP.  
The administration of any other concomitant treatment (steroids, anticonvulsive drugs) will be centre-
specific: each trial site will treat according to their guidelines.  
Study efficacy parameters and timing of post-treatment evaluations are based on WHO Draft Informal 
Consultation on the Conduct of Clinical Trials in Human African Trypanosomiasis (9Sept2004). 
Historically, a 24 months follow-up period has been aimed for in order to confirm clinical cure. This 
draft guideline is developed for both, the chronic T.b. gambiense as well as the acute T.b. rhodesiense 
sleeping sickness. This has been barely achieved in practise. Especially the very fast progressing T.b. 
rhodesiense sleeping sickness causes serious clinical signs and symptoms within a few days or weeks 
after infection. The logistic burden of follow-up visits for the patients and the health facilities is not in 
balance with the therapeutic conclusions one can draw at the 24 month follow-up visit. The drop-out 
rate increases significantly after 6-12 month; approximately 60-80% of subjects will be lost to follow of 
by 18 months post-treatment. However, based on the WHO Draft Informal Consultation on the 
Conduct of Clinical Trials in Human African Trypanosomiasis (9Sept2004), the end of treatment has 
been chosen as primary endpoint and the follow-up visits as secondary endpoint.  
The overall observed case fatality rate is approximately 9% and 10%, respectively according to the 
centre information (Lwala & Kaliua centres). The incidence of encephalopathic syndromes (ES) has 
been found to be in the order of 8% for Rhodesiense sleeping sickness with large inter-centre 
variations, of which about 50% have a fatal outcome. However, the infrastructure in field hospitals 
limits in-depth analysis of the cause of death, and it is therefore difficult to distinguish encephalopathic 
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syndromes with a fatal outcome (drug related) and fatalities with other cause of death (e.g. disease 
related, opportunistic infections – not drug related). Therefore the endpoint for the stopping rule is set 
to ≥10% of combined fatal outcome of treatment. This includes the incidence of encephalopathic 
syndromes with a fatal outcome and fatalities with other cause of death (e.g. disease related, 
opportunistic infections). This endpoint is equivalent to ≥7 patients for trials 1 & 2, respectively (N=30). 
Final data analysis will be performed after study closure (Refer to Section 7.4).  
 
Two trial sites will enrol subjects. Both trial sites will be equipped with all necessary laboratory 
materials. Anti-trypanocidal drugs are available through WHO. For the supply of all other drugs, the 
STI will purchase the required amount needed for the IMPAMEL III trials.  
 
The PCR-analysis for T.b. rhodesiense identification (SRA-gene) will be done in Uganda or 
Switzerland.  
The PCR analysis for distinction of relapses and re-infections will be done at Yale University, USA. 
 
5.2. Study Population 
Both, male and female subjects ≥ 6 years who meet all the inclusion criteria listed in Section 5.2.1 and 
exhibit none of the exclusion criteria listed in Section 5.2.2 of this protocol, will be eligible for 
enrolment. 
 
5.2.1. Criteria for Inclusion 
1. The patient has second stage T.b. rhodesiense infection; i.e. parasitologically confirmed infection 
in the blood or trypanosomes in CSF and/or WBC > 5 cells/mm3 in CSF detected by microscopic 
examination.  
2. Patient is male or female and ≥ 6 years of age. 
 
5.2.2. Criteria for Exclusion 
1. The patient has first stage T.b. rhodesiense infection; i.e. presence of trypanosomes in blood 
upon microscopic examination and no trypanosomes in CSF and/or ≤ 5cells/mm3. 
2. Moribund or unconscious patients are excluded from the trial. The eligibility is evaluated following 
the Glasgow coma scale (see Appendix 1). Patients with less than 8 points are excluded from the 
trial. 
3. Pregnant women are excluded from the trial. 
4. Active clinical relevant medical conditions that in the Investigators opinion may jeopardize subject 
safety or interfere with participation in the study, including but not limited: significant liver disease, 
chronic pulmonary disease, significant cardiovascular disease, diabetes and open tuberculosis. 
5. Critically ill patients with any condition which necessitates immediate and concomitant treatment 
not listed above.  
6. The subject has been previously enrolled in the study. 
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5.2.3. HIV 
1. On request, patients have the possibility to test their HIV status (in both trial sites HIV testing and 
counselling is normal practise).  
2. HIV positive patients will be referred to the countries respective National Control Program in order 
to receive treatment. 
3. HIV positive cases will be included in the trial when they meet all inclusion and exclusion criteria.  
 
5.2.4. Criteria for Discontinuation 
5.2.4.1. Discontinuation of Individual Subjects 
A subject can be discontinued from the study for the following reasons: 
1. Withdraws voluntarily from the study. 
2. At the discretion of the Principal Investigator if the patient is not compliant to the requirements 
of the protocol. 
If for any reason a subject is discontinued form the study before the end of treatment evaluation, the 
Investigator is required, as feasible, to perform the safety procedures planned for the end of treatment. 
If a subject develops an ES, he/she will remain under observation until the adverse event is resolved 
and stabilized.  
Subjects who discontinue the trial for any other reasons than drug or disease related reasons will be 
replaced (e.g. abandon of hospital, withdrawal of informed consent).  
 
5.2.4.2. Discontinuation of the Entire Study 
The entire study will be terminated if the combined endpoint (fatal ES and fatalities with other cause of 
death) is ≥10%, which corresponds to ≥ 7 patients in trial 1 & 2 (N=30).  
The STI may terminate this study prematurely; either for safety reasons, political unrests or census of 
false data. In the case of discontinuation of the entire study, the STI immediately notify the Investigator 
and subsequently provide written instructions for study termination.  
 
5.2.4.3. Scientific Advisory Board 
The study will be supervised by a SAB which supports and guides the IMPAMEL III program.  
Members of the Scientific Advisory Board: 
- Dr. Martin Odiit, MD, PhD, Uganda AIDS Commission, Kampala, Uganda 
- PD Dr. Blaise Genton MD, PhD, Swiss Tropical Institute, Basel, Switzerland 
- Prof. Lars Rombo MD, PhD, Dept. of Infectious Diseases, Eskilstuna, and Karolinska Institute 
Sweden 
- Prof. Martin Schumacher, University of Freiburg, Germany 
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5.3. Treatment 
5.3.1. Treatment schedule 
The IMPAMEL III program consists of trial 1 and trial 2 for (I) assessing the safety, tolerability and 
efficacy of the 10-day schedule in late stage T.b. rhodesiense patients and (II) for investigating the 
importance of the suramin pre-treatment. The iterative trial design has been chosen in order to 
compare parasitaemia, proteinuria and adverse drug reactions in patients who receive suramin and 
patients who get treated directly with melarsoprol. Each trial site will enrol 30 patients (15 patients in 
trial 1, 15 patients in trial 2). Trial 1 and trial 2 will be conducted consecutively. After ethical clearance 
is received, the study initiation will follow immediately. Best would be to start in both countries within 
close time periods in order to assure the availability of the results at similar time points.  
 
Table 2: Trial schema for Uganda 
Day of 
treatment 
Drug 
TRIAL 1 
Dose (mg/kg) 
TRIAL 2 
Dose (mg/kg) 
-1 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Suramin 
LP 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
5mg/kg 
-- 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
-- 
-- 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
 
Table 3: Trial schema for Tanzania: 
Day of 
treatment 
Drug 
TRIAL 1 
Dose (mg/kg) 
TRIAL 2 
Dose (mg/kg) 
-2 
-1 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Suramin 
Suramin 
LP 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
Melarsoprol 
5mg/kg 
20mg/kg 
-- 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
-- 
-- 
-- 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
2.2 
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Trial 1: 
Each subject of the study population will receive the suramin pre-treatment (dosage according centre 
specification). Melarsoprol treatment will start after 2 days in Uganda and 3 days in Tanzania. Each 
individual subject will receive melarsoprol continuously for 10 days at a dosage of 2.2 mg/kg (but a 
maximum of 180mg). 
 
Trial 2: 
If trial 1 shows a safe outcome, trial 2 will be initiated continuously. The defined study population will 
be treated with melarsoprol at a dosage of 2.2 mg/kg (but a maximum of 180mg) for 10 days 
continuously.  
No suramin will be administered.  
 
Table 4: Concomitant treatments during IMPAMEL III trials: 
Concomitant treatments 
Steroids   centre specific: Uganda:  Hydrocortison when reaction occurs. 
     Tanzania:  Prednisolone (10mg) half an hour before 
       melarsoprol administration. 
Anticonvulsive drugs  centre specific 
Paracetamol  Patients (≥ 30kg):  500mg every 12 hours  
   Patients (≤ 30kg):  250mg every 12 hours 
 
Facilities participating in the study will exclusively use the schedule described for all patients who gave 
consent. In facilities not participating, the standard treatment schedule and supplementary medication 
as foreseen by the National Authorities will be used without modifications.  
 
5.3.2. Additional Medication 
If National rules exist they are applicable for additional medication and therapy. Any additional 
medication applied that deviates from the standard procedures in a respective centre must be listed in 
detail in the CRF (i.e. date of prescription, drug, duration, justification).  
 
5.3.3. Drugs to avoid during the study 
The use of thiabendazole should be strictly omitted because it is under suspicion of precipitating 
reactive encephalopathies39. 
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5.3.4. Supplementary medication before melarsoprol treatment (standard if no rules exist) 
Malaria: centre specific diagnosis and treatment. 
Helminthic infections: centre specific diagnosis and treatment. 
Mebendazole: Day one to three: 100 mg total dose twice daily. 
Paracetamol: before and after LP. 
 
5.3.5. Supplementary medication during melarsoprol treatment 
Each patient will receive paracetamol twice a day (every 12 hours). Patients (≥ 30kg) receive twice 
500mg; patients (≤ 30kg) will receive twice 250mg.  
 
5.4. Procedure in case of severe adverse events 
5.4.1. Encephalopathy 
If preliminary signs of reactive encephalopathy are observed in a hospitalized patient (onset of fever 
and severe headaches) he has to be surveyed strictly. In case symptoms of reactive encephalopathy 
occur (convulsions, and/or confusion, coma) the melarsoprol treatment is interrupted. If no medical 
doctor is on site all efforts have to be made to get hold of him. All efforts have to be made that he is 
examined by a medical doctor immediately.  
If reactive encephalopathy is diagnosed melarsoprol treatment is suspended and the patient is treated 
following the rules of IMC or any participating partner. The interventions below may serve as guidelines. 
 Immediate treatment in case of reactive encephalopathy:  
- Adrenaline (epinephrine) may be given at 0.5 mg s.c. (to 1.0 mg max.) (0.5 ml of a 1:1000 solution, 1 
mg/ml), the maximal dose is 4 mg per 24 hours.  
- Corticosteroids (hydrocortison) at 1 g i.v., if the condition does not improve it may be repeated after 
some hours.  
 Additional treatment:  
- No specific rules exist for the application of anticonvulsive drugs against encephalopathies exists. The 
given indication (diazepam 0.4 mg/kg i.v., then 0.2 mg/kg per hour added to an infusion fluid, if 
possible) is based on 40, and glucose 5% or 10% infusions may be applied until the condition of the 
patient improves. 
- The patient is to be kept under permanent surveillance and good general nursing until the 
condition improves, then the melarsoprol treatment can be resumed after 1 to 3 days. Treatment 
is resumed at the position where the encephalopathy has occurred. If two or less doses are 
missing the treatment will be considered complete and will not be resumed. 
 
5.4.2. Other adverse events 
5.4.2.1. Neuropathies 
Neuropathies (sensitivity problems, severe pain when walking) are a phenomenon which occurs at 
largely different frequencies in different locations. If paraesthesias or severe pain occur which make 
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an intervention necessary, the melarsoprol treatment is interrupted until improvement of the 
symptoms. Then treatment is resumed. 
 
5.4.2.2. Skin Eruptions 
In case skin eruptions (especially severe maculopapular eruptions or the begin of bullous lesions) 
(“exfoliative dermatitis”) occur the medical doctor has to be informed. A differential diagnosis is made 
in order to discriminate possible treatment related problems and concomitant infections.  
The melarsoprol treatment is suspended if:  
1. Lesions in the mouth or on any other mucous tissue are visible 
2. Bullous lesions (exfoliative) are visible 
3. An extended, confluent maculopapular rash occurs 
After recovery the melarsoprol treatment is resumed with a third of the last used dose, at the following 
injection two thirds are applied, and then the full dose can be resumed. The patient has to remain 
hospitalized and kept under strict control. If two or less doses are missing the treatment will be 
considered complete and will not be resumed. 
 
5.4.2.3. Hypotension or collapse 
Collapse with slight hypotension: 
0.3 - 0.5 mg Adrenaline (epinephrine) (0.3 - 0.5 ml, 1:000, 1 mg/ml) s.c. 
Collapse with severe hypotension: 
0.3 - 0.5 mg adrenaline (3 -5 ml, 1:10’000) very slowly i.v.; may be repeated after 5 - 10 minutes. 
Complementary measures:  
Macrodex 5%, Hydrocortison i.v. 100 -2000 mg every 6 hours, antihistamines (Diphenhydramine - 
type) 25 - 50 mg / 6h 
 
5.5. Compliance 
The local investigator of the executing organization or Authority is responsible for complete 
compliance with the investigators manual of all the medical doctors, nurses and staff involved. 
- The investigator must agree and sign a document confirming that he or she understands the 
investigation and will work according to the protocol and Good Clinical Practice. 
- The investigator is responsible for ensuring that the protocol is strictly followed. The investigator 
should not make any changes without the agreement of the STI, except when necessary to eliminate 
an apparent immediate hazard or danger to a subject.  
- The investigator may take any steps judged necessary to protect the safety of the patients, whether 
specified in the protocol or not. Any such steps must be documented.  
- During the treatment the records are maintained by the responsible nurse or the medical doctor. All 
entries have to be made clearly readable with a pen. The records are controlled by the medical doctor 
before discharge of the patient, where ever possible.  
- The investigator must be thoroughly familiar with the properties, effects and safety of the 
investigational pharmaceutical product.  
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- Drugs are only applied by a medical doctor or a trained nurse assigned and adequately instructed. 
Exceptions in case of human resource constraints are allowed after discussion with the program 
director.  
 
6. Study Plan 
6.1.1. Pre-treatment Period 
The subjects will be recruited (I) during active surveillance in high prevalence villages and (II) among 
the patients reporting to one of the trial sites.  
 
The patients, who qualify for the study will be asked to provide written informed consent prior to 
undergoing any study specific procedures or treatment.  
 
For baseline evaluation following tests and procedures are to be performed: 
 Demographic information with height, weight, body mass index (calculated). 
 Complete medical history. For all women the fertility status will be noted (childbirth within 9 
months, no birth within last 2 years, no birth within last 5 years or menopause). 
 Signs and symptoms typical of HAT will be required and evaluated, if present according to the 
HAT symptom grading scale outlined in Appendix 2: chancre, lymphadenopathy, malaise, general 
body pain, joint pains, headache, temperature, pruritus, cough, swelling of legs, dyspnoea, heart 
rate, diarrhea, nutritional status, daytime sleep, night time sleep, tremor, speech impairment, 
abnormal movements, walking disability, general motor weakness, unusual behaviour, inactivity, 
aggressivity, appetite and fertility (females only). 
 Concomitant diseases and pre-treatment medications for the 7-day period prior to doing.  
 Vital signs including blood pressure, heart rate and temperature, taken in sitting position.  
 Physical examination and Glasgow Coma Scale (Appendix 1). 
 Pregnancy test. 
 Confirmatory tests for presence of trypanosomes in blood and/or lymph, and lumbar puncture for 
stage determination.  
 
The following tests will be performed in the order indicated to confirm the diagnosis of the screening 
examination with a maximum of 3 days prior to treatment initiation. Tests must be performed in order 
as indicated below; if a test is found to be positive for trypanosomes, subsequent tests need not to be 
performed: 
 Microscopic examination of blood (thin and/or thick smear). 
 Haematocrit centrifugation (WOO). 
A sample of CSF (5ml) will be obtained by LP and the following tests will be performed: 
 WBC count for stage determination (average of 3 countings). 
 Modified single centrifugation technique41: microscopic examination of CSF for trypanosomes. 
 
The subjects enrolled at a site will undergo following exams within 48 hours prior to dosing:  
 Blood sampling: for the performance of the tests listed, max. 5ml whole blood will be taken of 
each patient.  
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 Haematocrit centrifugation (WOO). 
 Haematology (haematocrit).  
 Quantifying the level of parasitaemia (thick blood film).  
 T.b. rhodesiense identification by PCR methodology (presence of SRA-gene). 
 Baseline data for each patient (blood collected on Gentra Cards). In case of a positive follow-up 
result, an additional blood sample will be taken. By comparison of the parasites genotype (PCR-
Methodology) the distinction of relapse vs. re-infection is possible.  
 HLA genotyping (blood collected on Gentra Cards). 
 Urine collection for dipstick analysis (Combur 9): Leucocytes, Nitrite, pH, Proteins, Glucose, 
Ketones, Urobilionogen, Bilirubine, Blood in urine, haemoglobin. 
 Subjects can require an HIV test (in the case of positive result they will be referred to the National 
Control Program). HIV positive patients can be included in the trial population.  
 
Eligibility will be determined by the inclusion / exclusion criteria. Subjects are admitted as in-house 
patients to the clinical site for the entire treatment period.  
 
Diagnosis and treatment of concomitant diseases such as malaria will be done according to current 
guidelines at the site before initiation of treatment with suramin. Treatment of filariasis will be 
postponed until completion of the application of trypanocidal drugs. Malaria will be tested on thin 
and/or thick smear of blood. Any diagnosis will be recorded as a part of the Medical History and any 
medications prescribed to treat newly diagnosed diseases will be recorded.  
 
6.1.2. Treatment Period 
6.1.2.1. Study Drug administration  
Suramin will be given to the patient under direct observation of an authorized staff member at 
approximately 08:00.  
Melarsoprol will be given to the patient under direct observation of an authorized staff member at 
approximately 08:00. Patients receive 10 melarsoprol injections at a dosage of 2.2mg/kg, the 
injections are spaced by 24 hours.  
Paracetamol will be given to the patients twice a day (every 12 hours). Patients with ≥ 30kg body 
weight will receive 2x500mg and patients with ≤ 30kg body weight 2x250mg. In the mornings, 
paracetamol administration follows just after melarsoprol administration. 12 hours later the patients 
receive the second dose pf paracetamol.  
Steroids will be administered according to the centres guidelines (= best supportive care). 
 
6.1.2.2. Procedures and Observations 
 Any concurrent medication taken during the treatment period will be recorded. 
 Any adverse signs and symptoms reported by the patient or noted during contact with the patient 
arising during the treatment period will be recorded. Refer to Appendix 4 for information regarding 
adverse event reporting requirements. 
 Vital signs will be recorded daily in the monitoring after each treatment dose. 
 Glucose and blood lipids (Cholesterol, HDL, LDL & triglycerides) will be measured daily (capillary 
blood sample). 
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 Urinary testing before first melarsoprol application. 
 
Remark: in the trial 2 patient group, all procedures are same, except there is no administration of 
suramin. Melarsoprol administration will start on day 1 directly.  
 
6.1.3. End of Treatment 
On study day 13 (Uganda) and study day 14 (Tanzania) for the trial 1 group and on study day 11 for 
the trial 2 group following tests will be performed in the order indicated:  
 Microscopic examination of blood (thin and/or thick smear).  
 Haematocrit centrifugation (WOO) 
 Haematology (haematocrit)  
 Vital signs 
 Urine analysis 
 Glucose and blood lipids (Cholesterol, HDL, LDL & triglycerides) 
 
In case of treatment failure: 
 LP 
 Blood will be collected for the distinction of a possible relapse or re-infection (PCR).  
 
Signs or symptoms of HAT will be queried and graded as outlined in Appendix 2: chancre, 
lymphadenopathy, malaise, general body pain, joint pains, headache, fever, pruritus, cough, swelling 
of legs, dyspnoea, heart rate, diarrhea, nutritional status, daytime sleep, night time sleep, tremor, 
speech impairment, abnormal movements, walking disability, general motor weakness, unusual 
behaviour, inactivity, aggressivity, appetite and fertility (females only). 
Concurrent medication taken during the study post treatment period (last day of study drug through 
discharge from the treatment centre) will be noted. 
 
Any adverse signs and symptoms reported by the patient or noted during contact with the patient 
arising between the initial dose of study drug and end of treatment evaluation will be recorded. For the 
purpose of this study, disease progression and relapse will be considered as treatment failure, not as 
an adverse event. Refer to Appendix 4 for information regarding adverse event reporting 
requirements. 
 
Before final discharge from the treatment centre, a physical examination, including vital signs and 
Glasgow Coma Scale, will be performed. Any deterioration in physical examination compared to the 
baseline examination should be reported as an adverse event.  
All subjects and parents or guardians of adolescents will be educated to watch for potential adverse 
events that may develop after the patients is discharged from the treatment centre, including signs and 
symptoms of ES. Should adverse events present, the subject should immediately return to the 
treatment centre for evaluation.  
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6.1.3.1. Subject Long-Term Follow-up 
The treating organization is responsible for the correct follow-up of the subjects. At the day of 
discharge each patient will receive a sleeping sickness treatment card that clearly indicated the dates 
of his/her follow-up visits. If support in transport is required, the IMPAMEL III program will cover the cost. 
In addition to the regular forms of the National Sleeping Sickness Program, the supplementary CRF 
forms provided for follow-up by STI must be used for every patient.  
 
All subjects will undergo the following exams at the 3 month post treatment visit:  
 Microscopic examination of blood (thin and/or thick smear).  
 Haematocrit centrifugation of blood (WOO). 
 Haematology (haematocrit).  
 Urine analysis (dipstick). 
Subjects will additional undergo a lumbar puncture. The WBC in the CSF will be counted. Microscopic 
examination of the CSF for trypanosomes will be performed (single modified centrifugation). 
In case of positive results an additional blood sample will be taken for PCR- analysis in order to 
determine if it is a relapse or re-infection. 
 
All subjects will undergo the following exams at the 6 month post treatment visit:  
 Microscopic examination of blood (thin and/or thick smear).  
 Haematocrit centrifugation of blood (WOO). 
 Haematology (haematocrit).  
Subjects will additional undergo lumbar puncture. The WBC in the CSF will be counted. Microscopic 
examination of the CSF for trypanosomes will be performed (single modified centrifugation). 
In case of positive results an additional blood sample will be taken for PCR- analysis in order to 
determine if it is a relapse or re-infection. 
 
All subjects will undergo the following exams at the 12 month post treatment visit:  
 Microscopic examination of blood (thin and/or thick smear).  
 Haematocrit centrifugation of blood (WOO). 
 Haematology (haematocrit). 
Subjects will additional undergo lumbar puncture. The WBC in the CSF will be counted. Microscopic 
examination of the CSF for trypanosomes will be performed (single modified centrifugation). 
In case of positive results an additional blood sample will be taken for PCR- analysis in order to 
determine if it is a relapse or re-infection. 
 
Signs or symptoms of HAT will be queried and graded as outlined in Appendix 2: chancre, 
lymphadenopathy, malaise, general body pain, joint pains, headache, temperature, pruritus, cough, 
swelling of legs, dyspnoea, hear rate, diarrhea, nutritional status, daytime sleep, night time sleep, 
tremor, speech impairment, abnormal movements, walking disability, general motor weakness, 
unusual behaviour, inactivity, aggressivity, appetite, fertility (females only).  
 
At month 12 an oral interview and physical examination will be performed.  
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For the purpose of determining appropriate clinical evaluation and follow-up, subjects will be classified 
according to the following descriptions as favourable evolution, uncertain evolution, relapse, re-
infection or death.  
 
In case of suspicion of relapse, whole blood will be collected for PCR testing. Any adverse signs and 
symptoms which are spontaneously reported between the end of treatment evaluation and 30 days 
post-treatment will be recorded. The Investigator will report all serious adverse events, regardless of 
the time of the event relative to the completion of treatment. Refer to Appendix 4 for information 
regarding adverse event reporting requirements. The patient will be asked about his/her current health 
status (well or unwell). If the patient is not available at any post treatment evaluation, data about the 
status of the patient (alive and well or unwell; death and cause of death) will be gathered from family, 
friends or local authorities. 
 
6.1.4. Monitoring for Safety 
Treatment emergent adverse signs or symptoms will be recorded in the adverse event section of the 
Case Report Form, along with date(s) of occurrence, duration, degree of severity, and probable 
relationship to study drug. The observation time for adverse events starts when the treatment is 
initiated and continues until discharge from the facility at the end of treatment. Any adverse signs and 
symptoms which are spontaneously reported between the end of treatment evaluation and 30 days 
post treatment will be recorded. The Investigator will report all serious adverse events, regardless of 
the time of the event relative to the completion of treatment. For the purpose of this trial, disease 
progression and relapse will be considered as treatment failure, not as an adverse event. Toxicity will 
be graded on a scale of 0 (no toxicity) to 4 using criteria in Appendix 3.  
 
Table 4: Toxicity Grading and Actions Taken in Response to Toxicity 
Toxicity Action Taken 
Grade 1: 
Mild toxicity, usually transient, requiring no special treatment 
and generally, not interfering with usual daily activities 
 
Observe patient closely and monitor laboratory 
parameters as needed. Patient may continue with 
study medication. 
Grade 2: 
Moderate toxicity ameliorated by simple manoeuvres 
 
Observe patient closely and monitor laboratory 
parameters as needed. Patient may need to 
discontinue study medication. 
If grade 2 toxicity is tolerated by patient, action 
same as grade 1. 
Grade 3: 
Severe toxicity which requires therapeutic intervention and 
interrupts usual activities; hospitalization may be prolonged. 
 
NOTIFY STUDY COORDINATOR IMMEDIATELY. 
Withhold test material. Monitor patient until event or 
toxicity decreases to Grade 2 or less. Discuss with 
study director whether to reinstitute treatment. 
Grade 4: 
Extremely severe or life-threatening 
 
NOTIFY STUDY COORDINATOR IMMEDIATELY. 
Discontinue test material treatment; monitor patient 
closely until event decreases to Grade 2 or less.  
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6.1.5. Collection and Reporting of Adverse Events 
Instructions for definitions, collecting and reporting of adverse events are included in Appendix 4. 
 
6.2. Efficacy and Safety Variables 
6.2.1. Appropriateness of Measurements 
Refer to Section 5.1. for discussion of the measurements to be used in the trial. 
 
6.2.2. Primary Efficacy Variables 
The primary efficacy variable will be the combined rate of clinical and parasitological cure (Table 5) at 
the end of treatment in the Per Protocol dataset (Section 6.1.3.). The combined rate of clinical and 
parasitological cure is defined as the proportion of treated subjects who have no clinical signs and 
symptoms of trypanosomiasis and no evidence for trypanosomes in any body fluid examined at all 
post treatment evaluations and not treated with other trypanosomiasis agent for any reason (early or 
late failure). At the end of treatment evaluation and at all follow-up visits lumbar puncture is performed 
and the cerebrospinal fluid (CSF) should contain ≤5 WBC/mm3.  
 
6.2.2.1. Secondary Efficacy Variables 
Parasitological cure, clinical cure, relapse, re-infection and death rates at the 3, 6, and 12 month 
evaluations will be determined. Parasitological cure, relapse, re-infection and death rates will also be 
assessed at the 12 month test of cure evaluation. Clinical cure will be considered equivalent to the 
parasitological cure at the 12 month evaluation. Clinical Response Definitions, based on WHO Draft 
Informal Consultation are outlined in Table 5 (below). For purposes of statistical analyses, each 
patient will be defined within one of the following categories at each post treatment assessment, 
based on the appropriate characteristics. 
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Table 5: Clinical Response Definitions 
Category WHO Term Patient Characteristics 
Parasitological 
Cure 
Cure Lumbar puncture performed: No evidence for parasitological 
relapse and ≤ 5 WBC/mm3 in CSF 
Clinical Cure  Probable Cure No evidence for parasitological relapse in absence of lumbar 
puncture (no clinical signs; symptoms / signs attributable to other 
disease; investigator decides no re-treatement necessary) or 
No parasitological evidence of relapse with ≤ 5 WBC/mm3 in CSF 
Action: No re-treatment 
Relapse Relapse Trypanosomes have been detected in any body fluid 
Action: Parasite DNA analysis by PCR Methodology in order to 
distinguish relapse from re-infection – parasite genotype equal to 
original determination  
Re-treatment 
Re-infection  Trypanosomes have been detected in any body fluid 
Action: Parasite DNA analysis by PCR Methodology in order to 
distinguish relapse from re-infection – parasite genotype different 
to original determination 
Re-treatment 
Death Death Death of patient during treatment or follow up; death will be 
categorized based on likely or definite cause of death as: 
 HAT 
 Adverse event related to treatment of HAT 
 Causes unrelated to HAT and treatment  
 Unknown causes 
 
6.2.3. Safety Variables 
The safety variables which will be evaluated through the end of treatment evaluation in this Phase II 
trial include: adverse events, vital sign measurements, laboratory results (blood, urine), physical 
examinations, and the use of any concomitant medications. Adverse events which are spontaneously 
reported between the end of treatment evaluation and 30 days post treatment will also be collected. 
The Investigator will report all serious adverse events, regardless of the time of the event relative to 
the completion of treatment. 
 
7. Statistical Methods 
7.1. Justification of Sample Size 
The sample size of 2x30 subjects is not based on formal statistical analysis, but is regarded based on 
clinical judgment as sufficient in this Phase II trial to assess the safety and efficacy objectives of the 
study. 
7.2. Efficacy Analysis 
The primary efficacy endpoint is the parasitological cure 24 hours after completion of treatment. A 
secondary endpoint is the parasitological cure 3, 6 and 12 months after completion of treatment. 
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7.3. Safety and Tolerability Analysis 
The primary outcome measure for safety is (I) death in temporal relationship to treatment. This 
includes the incidence of encephalopathic syndromes with a fatal outcome and fatalities with other 
cause of death (e.g. disease related, opportunistic infections). A combined endpoint of ≥ 10% has 
been set (N=30, CI=9.93 -42.28).  
 
7.4. Stopping rule 
Assuming a combined endpoint ≥ 10% of fatal outcome of treatment and a binomial distribution, then 
the probability of 7 or more events in 30 patients is approximately 0.026.  
Therefore the trial would be stopped if ≥7 patients for trials 1 & 2, respectively (N=30) would have a 
fatal outcome of their treatment. Final data analysis will be performed after study closure. 
 
7.5. Statistical and Analytical Plan 
The analytical plan will be developed during the execution of the study and added as an amendment 
to the protocol.  
 
 
8. Protocol Deviations 
When a variation from the protocol is deemed necessary for an individual subject, the investigator or 
other physician in attendance must contact the study coordinator (see Appendix 4). 
Such contact must be made as soon as possible to permit a decision as to whether or not the subject 
is to continue in the study. The deviation from the protocol will be authorized only for that subject.  
All deviations related to study inclusion and exclusion criteria and significant deviations to subject 
management and protocol procedures must be documented on the appropriate case report form. 
 
Changes to the protocol (after Signatures of Agreement are obtained) that affect the decision of the 
Ethics Committee (e.g., more extensive procedures, increased risk to subjects, changes in the subject 
population, additional safety information, etc.) must be documented in the form of an amendment. This 
amendment must be signed by the appropriate STI personnel and the Investigator, and approved by 
the Ethics Committee before it may be implemented. If the amendment is minor or reduces the risk to 
the subject, the chairperson of the Ethics Committee alone may approve it. Ethics Committee 
acceptance is not necessary for protocol clarifications that consist of minor protocol changes such as 
correcting typographical errors, rewording for clarity, changes in monitoring personnel, or for other 
changes to the protocol that do not affect the conduct of the study, including changes in the plan for 
statistical analysis. 
The only circumstances in which the amendment may be initiated without Ethics Committee 
acceptance is where the change is necessary to eliminate apparent immediate hazards to the 
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subjects. In that event, the Investigator must notify the Ethics Committee in writing within five (5) 
working days after the implementation. 
 
9. Ethics and Regulatory Requirements 
9.1. Ethical Clearance 
The study protocol was developed in accordance with the Declaration of Helsinki and the ICH 
Guidelines on Good Clinical Practice.  
Before study initiation the protocol must be approved by the Ethics Committee of the Kanton beider 
Basel (EKBB) and the Ethics Committee of the Ugandan Ministry of Health and the Tanzanian 
National Institute for Medical Research (NIMR).  
 
9.2. Ethical Conduct of the Study 
The IMPAMEL III trial is registered in the Current Controlled Trials (CCT, sister company of Biomed 
Central) database, which allow users to search, register and share information about clinical trials. 
The study will be conducted in accordance with the protocol, all ICH and GCP regulations governing 
clinical study conduct; ethical principles that have their origin in the Declaration of Helsinki (Appendix 
5), and all applicable local laws and regulations. The investigator must assure that the study is 
conducted complies with prevailing local laws and customs. Responsibilities of the Investigator are 
specified in Appendix 5. 
 
9.3. Subject Information and Consent 
Patients will receive the information on the benefits and risks of the treatment and will be asked for 
consent to get treatment. Every patient is given the choice to participate in the trial or to receive the 
standard treatment. For inclusion of children, the parents (or guardian or legal representative) are 
asked to sign the Informed Consent.  
 
9.4. Subject Confidentiality 
The investigators must ensure that the subject’s anonymity will be maintained. Subjects will be 
identified on the Case Report Forms by the Subject Number and Subject’s Initials in addition to centre 
and study identification information. The investigators will keep a separate confidential enrolment log 
that matches identifying codes with the subjects’ names and residencies. 
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10. Other Administrative and Regulatory Procedures 
10.1. Data Quality Assurance 
The National Coordinates are responsible for an adequate data quality.  
Prior to the initiation of the study, an investigator’s meeting will be held with the investigators and their 
study coordinators and staff from STI. This meeting will include a detailed discussion of the protocol, 
performance of study procedures, CRF completion, and specimen collection methods. In addition to 
the investigator’s meeting, the study personnel at each site will be trained on the study procedures by 
STI personnel at a study initiation visit. 
STI personnel will monitor each site throughout the study. Source document review will be performed 
against entries on the CRF and a quality assurance check will be performed to ensure that the 
investigator is complying with the protocol and regulations. In addition, after CRFs are retrieved by the 
STI personnel. A review of the data will be conducted by a physician and a clinical review team at STI.  
All data hand entered in the database will be verified by a double-key entry procedure. Any 
discrepancies will be reviewed against the hard copy CRF and corrected on-line. After completion of 
the entry process, computer logic checks will be run to check for such items as inconsistent study 
dates and outlying laboratory values. Any necessary corrections will be made to the database and 
documented via addenda or audit trail. A manual review of selected line listings will also be performed 
at the end of the study. 
 
10.2. Source Documents, Case Report Forms (CRFs) 
All CRFs will be controlled for completeness locally. The data will be double-entered into a DMSys 
database prepared by the study coordinator. The quality of the final database is a subject to auditing 
by the PMU.  
Subject source documents are the physician’s subject records maintained at the study site.  In most 
cases, the source documents will be the hospital’s or the physician’s chart.  In cases where the source 
documents are the hospital’s or the physician’s chart, the information collected on the CRFs must 
match those charts. In some cases, a portion of the source documents for a given subject may be the 
CRFs. 
The CRFs will be printed on CR (“carbon required”) paper to permit multiple copies. The bottom copy 
is to be retained at the site for the Investigator’s study file. All questions should be answered using a 
black ink ballpoint pen. If certain data are not available, not done, or not applicable:  “NAV,” “ND,” or 
“NAP,” respectively, will be entered in the appropriate space. 
Twenty-four hour clock should be used for all time entries. Changes and/or additions to data entered 
on original CRFs must be made in the following manner: The original entry will be lined out with a 
single line drawn through the error (not erased or “whited out”) so as to leave it still legible. The 
correction will be entered using a black ink ballpoint pen, initialled, and dated by the person making 
the correction. The Investigator or delegate (e.g., Sub-Investigator or study coordinator), may enter 
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corrections on original CRFs. The monitoring team may make changes to the copies of CRFs based 
on information supplied by the Investigator and documented in the study file. 
An STI staff member or assigned consultant will bring the CRFs to the STI.  
An STI staff member or assigned consultant will visit the study site for the purpose of comparing the 
data on the CRFs with the source documents.  The Investigator agrees to make source documents 
available for this purpose. 
The CRFs should be completed as soon as possible after the data are available.  
 
10.3. Maintenance of Records 
The Investigator will maintain all study documents: 
a. for a minimum of two years after study closure.  
OR 
b. for any longer period that is specified by the regulatory requirements of the country in 
which the study site is located. 
If the Investigator relocates, retires, or for any reason withdraws from the study, the study records may 
be transferred to an acceptable designee, such as another Investigator, another institution, or to STI. 
The Investigator must obtain STI’s permission before disposing of any records. 
It is the responsibility of the STI to inform the investigator/institution as to when these documents no 
longer need to be retained. 
 
10.4. Completion of the Study 
The investigator will conduct this study in compliance with the protocol, and will complete the study in 
satisfactory compliance with the protocol within 8 weeks after the last evaluation of the last subject or 
within 8 weeks of the designated completion date. The investigator will provide a summary of the 
study’s outcome to the IEC and the STI.  
 
10.4.1. Final Report 
Upon request by the Investigator, at the completion of the study and following analysis of the data, STI 
will supply a listing of the Investigator’s subjects’ treatment assignments, tabulated data, and statistical 
analyses, as appropriate. A copy of the final study report and corrected CRFs and/or change 
requisitions including a receipt to be signed and returned to STI will be provided to each Investigator 
following its release.  
 
10.4.2. Use of Information 
All information concerning the IMPAMEL III project belongs to the STI and is confidential (e.g. basic 
scientific data, or and not previously published is considered confidential information). 
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The information developed during the conduct of this clinical study is also considered confidential and 
will be used by the STI. To allow for the use of the information derived from this clinical study and to 
ensure complete and thorough analysis, the investigator is obligated to provide STI with complete test 
results and all data developed in this study and to provide direct access to source data/documents for 
trial-related monitoring.  
 
10.5. Publication 
The final results of the investigations will be published in scientific journals and at seminars or 
conferences.  
All results from investigations are considered confidential and shall not be made available to any third 
part by any member of the investigating team before publication.  
A restrictive definition of authorship of any publications will be applied:  
Any author must have made significant contributions to (a) the conception and design, or analysis and 
interpretation of the data; and to (b) drafting the article or revising it critically for important intellectual 
content; and on (c) final approval of the version to be published. Each author must have participated 
sufficiently in the work to take public responsibility for the total content of the publication. 
The guidelines follow recent publication regarding this issue42. 
The study coordinator will be the first author of the main scientific papers to be published. Country 
coordinators will be considered as co-authors for publications containing data from their countries, 
provided a continuous active participation throughout the conduct of the project, e.g. from drafting the 
study protocol to the writing of the manuscript is warranted.  
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10.6. Country Specific Investigator’s Signature Page 
 
1.  I have read this protocol and agree to conduct the study as outlined and in accordance with all 
applicable local, state, and federal regulations. 
2.  I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol. 
 
 
__________________________________________________        _________________ 
Signature of Local Principal Investigator     Date 
 
__________________________________________________ 
Printed Name of Local Principal Investigator 
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Appendix 1 Glasgow Coma Scale (adapted) 
 
Adults Reaction Score 
Best verbal response Oriented 
Confused 
Inappropriate words 
Incomprehensive Sounds 
None 
5 
4 
3 
2 
1 
Best Motor Response Obeys Commands 
Directed Defensive Response 
Non-directed Defensive Response 
Flexion to Pain 
Extension to Pain 
None 
6 
5 
4 
3 
2 
1 
 Total 2-11 
 Considered unrousable coma ≤ 7 
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Appendix 2 Grading of Clinical Signs and Symptoms of HAT 
 
 Grade 0 Grade 1 Grade 2 
Chancre absent present  
Lymphadenopathy absent palpable (> 1 cm)  
Malaise absent present unbearable 
General body pain absent present unbearable 
Joint pains absent present unbearable 
Headache absent present unbearable 
Fever absent > 37.5ºC  
Pruritus absent present visible traces of scratching 
Cough absent non-productive productive 
Swelling of legs no swelling swelling limited to foot Swelling whole leg 
Dyspnoea none or no change on exertion at rest 
Heart rate regular non-regular  
Diarrhea Absent 3 stools in the last 24 
hours 
More than 3 stools in the last 
24 hours 
Nutritional Status malnourished suboptimal normal 
Daytime sleep normal repeatedly continuously 
Night time sleep normal few hours rare 
Tremor absent visible severe 
Speech impairment absent present uninterpretable speech 
Abnormal movements absent present inability to perform daily tasks 
Walking disability absent walking with difficulties walking with help  
or inability to walk 
General motor weakness absent  ability to stand up from 
chair without use of 
hands 
no ability to stand up from 
chair without use of hands 
Unusual behaviour absent present severe 
Inactivity absent reduced workforce inability to perform daily tasks 
Aggressive behaviour absent sporadic severe, requires observation 
Appetite normal disturbed severely disturbed 
Fertility (females only) Birth within last 9 
months 
No birth within last 2 
years 
No birth within last 5 years or 
menopause 
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Appendix 3 Toxicity Grading Scale 
WHO (World Health Organization) Toxicity Criteria by Grade 
Category Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Haematology  WBC (x103/l)  > 4  3.0 - 3.9  2.0 - 2.9  1.0 - 1.9  < 1.0  
Haematology  Hct(%)  > 40-54% (for 
men), > 37-
47% (for 
women) 
> 39% (for 
men), > 36% 
(for women)  
<39% (for 
men), < 36% 
for women 
< 32% (for 
men), < 29% 
for women 
 
< 25% (for men),       
< 22% (for women) 
Metabolic 
(fasting) 
Hyperglycaemia 
(mg/dl)  
< 116  116 - 160  161 - 250  251 - 500  > 500 or ketoacidosis  
Metabolic 
(fasting) 
Hypoglycaemia 
(mg/dl)  
> 64  55 - 64  40 - 54  30 - 39  < 30  
Gastrointestinal  Nausea  None  able to eat 
reasonable 
intake  
intake 
significantly 
decreased 
but can eat  
no significant 
intake  
__  
Gastrointestinal  Vomiting  None  1 episode in 24 
hrs  
2 - 5 
episodes in 
24 hrs  
6 - 10 
episodes in 24 
hrs  
> 10 episodes in 24 
hrs or requiring 
parenteral support  
Gastrointestinal  Diarrhoea  None  increase of 2 - 3 
stools / day over 
pre-Rx  
increase of 4 
- 6 stools / 
day, or 
nocturnal 
stools, or 
moderate 
cramping  
increase of 7 - 
9 stools / day, 
or 
incontinence, 
or severe 
cramping  
increase of > 10 
stools / day or grossly 
bloody diarrhoea, or 
need for parenteral 
support  
Gastrointestinal  Stomatitis  None  painless ulcers, 
erythema, or 
mild soreness  
painful 
erythema, 
oedema, or 
ulcers but 
can eat 
solids  
painful 
erythema, 
oedema, or 
ulcers and 
cannot eat 
solids  
requires parenteral or 
enteral support for 
alimentation  
Liver  Liver- clinical  No change 
from baseline  
  -----    -----  Pre-coma  hepatic coma  
Kidney, bladder  Proteinuria  No change  1 (+) or < 0.3 
g% or 3 g/L  
2 - 3 (+) or 
0.3 - 1.0 g% 
or 3 - 10 g/L  
4 (+) or > 1.0 
g% or > 10g/L  
nephrotic syndrome  
Kidney, bladder  Haematuria  Negative  microscopic only gross, no 
clots no Rx 
needed  
gross and 
clots bladder 
irrigation  
requires trans- fusion 
or cystectomy  
Pulmonary  Pulmonary  none or no 
change  
asymptomatic, 
with abnormality 
in PFTs  
dyspnoea on 
significant 
exertion  
dyspnoea at 
normal level of 
activity  
dyspnoea at rest  
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Category Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Cardiac  Cardiac arrhythmias  none  asymptomatic, 
transient, 
requiring no 
therapy  
recurrent or 
persistent, 
no therapy 
required  
requires 
treatment  
requires monitoring; 
or hypo- tension, or 
ventricular 
tachycardia or 
fibrillation  
Neurologic  Neuro: sensory  none or no 
change  
mild 
paraesthesias; 
loss of deep 
tendon reflexes  
mild or 
moderate 
objective 
sensory loss 
moderate 
paraesthesia
s  
severe 
objective 
sensory loss 
or 
paraesthesias 
that interfere 
with function  
-----  
Neurologic  Neuro: motor  none or no 
change  
subjective weak- 
ness; no 
objective 
findings  
mild 
objective 
weakness 
without 
significant 
impairment 
of function  
objective 
weak- ness 
with 
impairment of 
function  
paralysis  
Neurologic  Neuro: cortical  none  mild 
somnolence or 
agitation  
moderate 
somnolence 
or agitation  
severe 
somnolence, 
(>50 % waking 
hours), 
agitation, 
confusion, 
disorientation 
or 
hallucinations  
coma, seizures, toxic 
psychosis  
Neurologic  Neuro: cerebellar  none  slight 
incoordination, 
dysdiadochokine
sia  
intention 
tremor, 
dysmetria, 
slurred 
speech, 
nystagmus  
locomotor 
ataxia  
cerebellar necrosis  
Neurologic  Neuro: mood  no change  mild anxiety or 
depression  
moderate 
anxiety or 
depression  
severe anxiety 
or depression  
suicidal ideation  
Neurologic  Neuro: headache  none  mild  moderate or 
severe but 
transient  
unrelenting 
and severe  
-----  
Neurologic  Neuro: constipation  none or no 
change  
mild  moderate  severe  ileus > 96 hrs  
Neurologic  Neuro: hearing  none or no 
change  
asymptomatic, 
hearing loss on 
audiometry only  
tinnitus  hearing loss 
interfering with 
function but 
correctable 
with hearing 
aid  
deafness not 
correctable  
Neurologic  Neuro: vision  none or no 
change  
-----  -----  symptomatic 
subtotal loss of 
vision  
blindness  
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Category Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Pain  Pain  none  mild  moderate  severe  reg. narcotics  
Skin  Skin  none or no 
change  
scattered 
macular-papular 
eruption or 
erythema that is 
asymptomatic  
scattered 
macular or 
papular 
eruption or 
erythema 
with pruritus 
or other 
associated 
symptoms  
generalised 
symptomatic 
macular, 
papular or 
vesicular 
eruption  
exfoliative dermatitis 
or ulcerating 
dermatitis  
Allergy  Allergy  none  transient rash, 
drug fever < 
38°C (100.4°F)  
urticaria, 
drug fever 
38°C 
(100.4°F), 
mild 
bronchospas
m  
serum 
sickness, 
bronchospasm 
requiring 
parenteral 
medication  
anaphylaxis  
Local  Local  none  pain  pain and 
swelling with 
inflammation 
or phlebitis  
ulceration  plastic surgery 
indicated  
Fever of 
unknown origin  
Fever of unknown 
origin  
none  37.1 - 38.0°C 
98.7 - 100.4°F  
38.1 - 40.0°C 
100.5 - 
104°F  
> 40.0°C  
(> 104.0°F) for 
less than 
24hrs  
> 40.0°C (>104°F) for 
more than 24 hrs or 
accompanied by 
hypotension  
Infection  Infection  none  mild  moderate  severe  life-threatening  
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Appendix 4 Administrative Procedures for the Reporting of Adverse Events 
 
Adverse Event 
The Investigator will be required to provide appropriate information concerning any findings that 
suggest significant hazards, contraindications, side effects, or precautions pertinent to the safety of the 
treatment schedule under investigation.  
 
Types of adverse events 
The term adverse event could include any of the following events which develop or increase in the 
severity during the course of the study: 
1. Any signs or symptoms whether thought to be related to the condition under study; 
2. Any abnormality detected during physical examination. 
These data will be recorded on the appropriate CRFs, regardless of whether they are thought to be 
associated with the study or the drug under investigation. Associated with the use of the drug means 
that there is a reasonable possibility that the event may have been caused by the drug, respectively by 
the treatment schedule.  
 
Adverse signs or symptoms will be graded by the Investigator as mild, moderate, severe, or intolerable 
according to the following definitions: 
Grade Definition 
(1) Mild: 
(2) Moderate: 
(3) Severe: 
(4) Intolerable: 
Causing no limitations of usual activities 
Causing some limitations of usual activities 
Causing inability to carry out usual activities 
Intolerable or life-threatening 
The observation time for adverse events starts when the treatment is initiated and continues until 5 
days post-treatment. Any adverse signs and symptoms which are spontaneously reported between 
the end of treatment evaluation and 30 days post treatment will be recorded. For the purpose of the 
trial, disease progression and relapse will be considered as treatment failure, not as an Adverse 
Event. Cases of re-infection will not be considered as treatment failure.  
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Relationship to the Study Drug 
The investigator will use the following definitions to assess the relationship of the adverse event to the 
use of the study drug: 
 
Probably related An adverse event has a strong temporal relationship to study drug, or 
recurs on re-challenge and etiology is unlikely or significantly less 
likely. 
Probably not related An adverse event has a strong temporal relationship to the study 
drug and an alternative etiology is equally or less likely compared to 
the potential relationship to the study drug. 
Possibly related An adverse event has little or no temporal relationship to the study 
drug and/or more likely alternative etiology exists. 
Not related An adverse event is due to an underlying or concurrent illness or 
effect of another drug and is not related to the study drug (e.g. has no 
temporal relationship to study drug or has much more likely 
alternative etiology.  
If an investigator’s opinion of possibly, probably not, or not related to study drug is given, an 
alternative etiology must be provided by the investigator of the adverse event.  
 
Serious Adverse Event 
A “serious” adverse event is defined as any event that suggests a significant hazard, contraindication, 
side effect, or precaution. A serious adverse event includes any event that: 
1. is fatal 
2. is life threatening, meaning, the subject was, in the view of the Investigator, at immediate risk of 
death from the reaction as it occurred, i.e., does not include a reaction that, had it occurred in a 
more serious form, might have cause death; 
3. is a persistent or significant disability or incapacity, i.e., the event causes a substantial disruption 
of a person’s ability to conduct normal life function; 
4. requires, or prolongs in-patient hospitalization; 
5. is a congenital anomaly or birth defect; 
6. Is an important medical event, based upon appropriate medical judgment that may jeopardize the 
patient or subject or may require medical or surgical intervention to prevent one of the other 
outcomes defining serious.  
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Reporting Obligations 
All “serious” events, whether or not unexpected or considered to be associated with the use of drug, 
and regardless of the timing of the occurrence after the first dose of study drug, must be 
communicated immediately upon discovery of the event, and within 24 hours of discovery, either by 
telephone or email.  
Contact:  Study coordinator 
  Irène Kuepfer 
  Swiss Tropical Institute 
  Socinstrasse 57 
  CH-4002 Basel, 
  Fax +41 61 225 26 78 
  Tel +41 61 225 26 68 
  Email: Irene.Kupefer@unibas.ch 
 
 
Follow-up of adverse events 
All Serious Adverse Events must be followed with appropriate medical management until resolved or 
until considered chronic and stable or otherwise explained. If the treatment was interrupted due to an 
adverse event, it may be resumed if considered both safe and ethical. The minimum coherent duration 
of treatment must be maintained if the patient is re-treated. 
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Appendix 5 Ethical Consideration and Human Subject Protection 
Investigators and Study Sites 
The investigators who are responsible for the conduct of this study, in compliance with this protocol, 
are identified on the Signatures of Agreement page. 
 
Ethics Committee Acceptance 
 It is required that a valid Ethics Committee approves in writing the conduct of this clinical study, 
together with the Investigator’s informed consent document, prior to study initiation.  
 The trial protocol was developed in accordance with the Declaration of Helsinki and the ICH 
Guidance on Good Clinical Practice.  
 In performing this study, both the Investigator and Sponsor endorse, as a minimum, the 
standards for conduct of clinical research activities as set forth in the Declaration of Helsinki, ICH 
guidelines and local country laws and regulations.  
 The Study Director will submit the protocol and informed consent for Ethics Committee 
acceptance. This will be appropriately documented. The Ethics Committee should be asked to 
give its acceptance in writing. The names and qualifications of the members of the review 
committee will be recorded and submitted to the Swiss Tropical Institute together with the written 
acceptance for the conduct of the study.  
 The members of the Ethics Committee accepting must be independent of the sponsor and the 
Investigator.  
 The written acceptance should consist of a completed Ethics Committee Acceptance form or 
written documentation from the Ethics Committee containing the same information.  
 Until written acceptance by the Ethics Committee has been received by the Sponsor, no subject 
may undergo any procedures solely for the purpose of determining eligibility for this study.  
 Protocol amendments must also be reviewed and accepted by the Ethics Committee and written 
acceptance from the committee or at least the chairperson (or a designated committee member) 
must be received by the Swiss Tropical Institute before implementation. This written approval will 
consist of a completed Ethics Committee Acceptance form or written documentation from the 
Ethics Committee containing the same information. 
 Additional, the IMPAMEL III trial is registered in the Current Controlled Trials (CCT, sister company 
of Biomed Central) database, which allows users to search, register and share information about 
clinical trials.  
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Declaration of Helsinki 
World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in 
Biomedical Research Involving Human Subjects 
Adopted by the 18th World Medical Assembly, Helsinki, Finland 1964 and as revised by the World 
Medical Assembly in Tokyo, Japan 1975, in Venice, Italy, 1983, and Hong Kong in 1989.  
 
Introduction 
It is the mission of the physician to safeguard the health of the people. His or her knowledge and 
conscience are dedicated to the fulfilment of this mission.  
The Declaration of Geneva of the World Medical Association binds the physician with the words, "The 
health of my patient will be my first consideration,” and the International Code of Medical Ethics 
declares that, "A physician shall act only in the patient's interest when providing medical care which 
might have the effect of weakening the physical and mental condition of the patient. "  
The purpose of biomedical research involving human subjects must be to improve diagnostic, 
therapeutic and prophylactic procedures and the understanding of the etiology and pathogenesis of 
disease.  
In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. 
This applies especially to biomedical research.  
Medical progress is based on research which ultimately must rest in part on experimentation involving 
human subjects. In the field of biomedical research a fundamental distinction must be recognised 
between medical research in which the aim is essentially diagnostic or therapeutic for a patient, and 
medical research the essential object of which is purely scientific and without implying direct 
diagnostic or therapeutic value to the person subjected to the research.  
Special caution must be exercised in the conduct of research which may affect the environment, and 
the welfare of animals used for research must be respected.  
Because it is essential that the results of laboratory experiments be applied to human beings to further 
scientific knowledge and to help suffering humanity, the World Medical Association has prepared the 
following recommendations as a guide to every physician in biomedical research involving human 
subjects. They should be kept under review in the future. It must be stressed that the standards as 
drafted are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil 
and ethical responsibilities under the law of their own countries.  
 
I. Basic Principles 
1. Biomedical research involving human subjects must conform to generally accept scientific 
principles and should be based on adequately performed laboratory and animal 
experimentation and on a thorough knowledge of the scientific literature.  
2. The design and performance of each experimental procedure involving human subjects 
should be clearly formulated in an experimental protocol which should be transmitted to a 
specially appointed independent committee for consideration, comment and guidance.  
3. Biomedical research involving human subjects should be conducted only by scientifically 
qualified persons and under the supervision of a clinically competent medical person. The 
responsibility for the human subject must always rest with a medically qualified person and 
never rest on the subject of the research, even though the subject has given his or her 
consent.  
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4. Biomedical research involving human subjects cannot legitimately be carried out unless the 
importance of the objective is in proportion to the inherent risk to the subject.  
5. Every biomedical research project involving human subjects should be preceded by careful 
assessment of predictable risks in comparison with foreseeable benefits to the subject or to 
others. Concern for the interests of the subject must always prevail over the interests of 
science and society.  
6. The right of the research subject to safeguard his or her integrity must always be respected. 
Every precaution should be taken to respect the privacy of the subject and to minimize the 
impact of the study on the subject's physical and mental integrity and on the personality of the 
subject.  
7. Physicians should abstain from engaging in research projects involving human subjects 
unless they are satisfied that the hazards involved are believed to be predictable. Physicians 
should cease any investigation if the hazards are found to outweigh the potential benefits.  
8. In publication of the results of his or her research, the physician is obliged to preserve the 
accuracy of the results. Reports of experimentation not in accordance with the principles laid 
down in this Declaration should not be accepted for publication.  
9. In any research on human beings, each potential subject must be adequately informed of the 
aims, methods, anticipated benefits and potential hazards of the study and the discomfort it 
may entail. He or she should be informed that he or she is at liberty to abstain from 
participation in the study and that he or she is free to withdraw visor her consent to 
participation at any time. The physician should then obtain the subject's freely given informed 
consent, preferably inheriting.  
10. When obtaining informed consent for the research project the physician should be particularly 
cautious if the subject is in dependent relationship to him or her or may consent under duress. 
In that case the informed consent should be obtained by a physician who isn't engaged in the 
investigation and who is completely independent of this official relationship.  
11. In case of legal incompetence, informed consent should be obtained from the legal guardian in 
accordance with national legislation. Where physical or mental incapacity makes it impossible 
to obtain informed consent, or when the subject is a minor, permission from the responsible 
relative replaces that of the subject in accordance with national legislation. Whenever the 
minor child is in fact able to give consent, the minor's consent must be obtained in addition to 
the consent of the minor's legal guardian.  
12. The research protocol should always contain a statement of the ethical considerations 
involved and should indicate that the principles enunciated in the present declaration are 
complied with.  
 
II. Medical Research Combined with Professional Care (Clinical Research) 
1. In the treatment of the sick person, the physician must be free to use a new diagnostic and 
therapeutic measure, if in his or her judgement it offers hope of saving life, re-establishing 
health or alleviating suffering.  
2. The potential benefits, hazards and discomfort of a new method should be weighed against 
the advantages of the best current diagnostic and therapeutic methods.  
3. In any medical study, every patient- including those of a control group, if any- should be 
assured of the best proven diagnostic and therapeutic method.  
4. The refusal of the patient to participate in a study must never interfere with the physician-
patient relationship.  
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5. If the physician considers it essential not to obtain informed consent, the specific reasons for 
this proposal should be stated in the experimental protocol for transmission to the independent 
committee (1, 2).  
6. The physician can combine medical research with professional care, the objective being the 
acquisition of new medical knowledge, only to the extent that medical research is justified by 
its potential diagnostic or therapeutic value for the patient.  
 
III. Non-Therapeutic Biomedical Research Involving Human Subjects (Non-Clinical Biomedical 
Research) 
1. In the purely scientific application of medical research carried out on a human being, it is the 
duty of the physician to remain the protector of the life and health of that person on whom 
biomedical research is being carried out.  
2. The subjects should be volunteers- either healthy persons or patients for whom the 
experimental design is not related to the patient's illness.  
3. The investigator or the investigating team should discontinue the research if in his/her or their 
judgment it may, if continued, be harmful to the individual.  
4. In research on man, the interest of science and society should never take precedence over 
considerations related to the well-being of the subject.  
 
Informed Consent 
The Investigator will obtain informed consent from each subject enrolled in the study, in accordance 
with the Declaration of Helsinki, the current versions of the ICH guidelines and the laws and 
regulations of the country in which the investigation is being conducted.  
The Ethics Committee must accept the informed consent document to be used by the Investigator. It is 
the responsibility of the Investigators to assure that the patient (or guardian or legal representative) 
has signed the Informed Consent before any activity or treatment is undertaken which is not part of 
routine care. This includes, but is not limited to, the performance of diagnostic ort therapeutic 
procedures and the administration of the first dose of the study medication. 
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Appendix 6 Essential Documents  
Prior to the beginning of any clinical study, the Investigator will be asked to provide the following 
documents to STI:  
1. A current curriculum vita of the investigator. If sub-investigators will participate in the study, 
curriculum vitae for each are to be provided. 
2. Requirements for the Independent Ethics Committee (IEC). 
3. A copy of the signed and dated letter of approval of the IEC. The letter must specify that both the 
protocol and informed consent form were approved (unless separate documentation that the 
informed consent was approved is provided).  
4. A dated list containing the names and affiliations of the members of the IEC.  
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